Skip to Main Content
DownloadHi-Res Photo

Eric Winer, MD

Professor of Medicine (Medical Oncology); Director, Yale Cancer Center; Physician-in-Chief, Smilow Cancer Network; Alfred Gilman Professor, Medicine and Pharmacology

Contact Information

Eric Winer, MD
Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Over the past decade, I have focused on developing new therapies for women with breast cancer and directed more of my attention to basic and translational research. I have secured peer-reviewed funding from the Avon Partners for Progress Program, the Komen Foundation, and the Breast Cancer Research Program.

Extensive Research Description

Over the past decade, I have focused on developing new therapies for women with breast cancer and directed more of my attention to basic and translational research. I have secured peer-reviewed funding from the Avon Partners for Progress Program, the Komen Foundation, and the Breast Cancer Research Program.

Coauthors

Research Interests

Breast

Selected Publications

  • Exploring the impact of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery.Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer 2022, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.
  • The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention.Delahanty LM, Wadden TA, Goodwin PJ, Alfano CM, Thomson CA, Irwin ML, Neuhouser ML, Crane TE, Frank E, Spears PA, Gillis BP, Hershman DL, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hudis C, Winer EP, A Carey L, Partridge AH, Ligibel JA. The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. Obesity (Silver Spring, Md.) 2022, 30: 28-38. PMID: 34932888, DOI: 10.1002/oby.23287.
  • Genomic features of rapid versus late relapse in triple negative breast cancer.Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.
  • The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. JCI Insight 2021, 6 PMID: 33886505, PMCID: PMC8262355, DOI: 10.1172/jci.insight.147617.
  • Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discovery 2021, 11: 2474-2487. PMID: 33941592, PMCID: PMC8598376, DOI: 10.1158/2159-8290.CD-20-1557.
  • Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2021, 39: 2247-2256. PMID: 33999652, PMCID: PMC8260904, DOI: 10.1200/JCO.21.00280.
  • Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2021, 39: 2375-2385. PMID: 34077270, DOI: 10.1200/JCO.20.03398.
  • Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Research And Treatment 2021, 189: 103-110. PMID: 34120223, DOI: 10.1007/s10549-021-06267-8.
  • Reply to M. Tanaka et al.Tolaney SM, Partridge AH, Winer EP, Krop IE. Reply to M. Tanaka et al. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2021, 39: 3648-3649. PMID: 34506210, DOI: 10.1200/JCO.21.01967.
  • Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications 2021, 12: 5563. PMID: 34548479, PMCID: PMC8455578, DOI: 10.1038/s41467-021-25769-z.
  • Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, 40: 438-448. PMID: 34890214, PMCID: PMC8824393, DOI: 10.1200/JCO.21.00896.
  • Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, Hamilton EP, Hurvitz SA, Rugo HS, Curigliano G, Tolaney SM. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2022, 33: 234-238. PMID: 34942341, DOI: 10.1016/j.annonc.2021.12.004.
  • Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, DeMeo M, Burstein HJ, Partridge AH, Winer EP, Krop IE, Tolaney SM. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal Of Radiation Oncology, Biology, Physics 2022, 113: 117-124. PMID: 34990776, DOI: 10.1016/j.ijrobp.2021.12.173.
  • Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review.Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolaney SM. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. JAMA Oncology 2022, 8: 629-635. PMID: 35024766, DOI: 10.1001/jamaoncol.2021.6597.
  • CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, 40: 1323-1334. PMID: 35044810, PMCID: PMC9015203, DOI: 10.1200/JCO.21.01506.
  • Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer 2022, 8: 18. PMID: 35173164, PMCID: PMC8850608, DOI: 10.1038/s41523-022-00385-2.
  • The Global Landscape of Treatment Standards for Breast Cancer.Trapani D, Douillard JY, Winer EP, Burstein H, Carey LA, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G, Ilbawi AM. The Global Landscape of Treatment Standards for Breast Cancer. Journal Of The National Cancer Institute 2021, 113: 1143-1155. PMID: 33502535, DOI: 10.1093/jnci/djab011.
  • Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. Journal Of The National Cancer Institute 2021, 113: 1005-1016. PMID: 33523233, PMCID: PMC8328980, DOI: 10.1093/jnci/djab004.
  • Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.Lynce F, Williams JT, Regan MM, Bunnell CA, Freedman RA, Tolaney SM, Chen WY, Mayer EL, Partridge AH, Winer EP, Overmoyer B. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemotherapy And Pharmacology 2021, 87: 673-679. PMID: 33585999, DOI: 10.1007/s00280-021-04245-x.
  • Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research And Treatment 2021, 187: 843-852. PMID: 33590387, DOI: 10.1007/s10549-021-06121-x.
  • A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer.Bellon JR, Chen YH, Rees R, Taghian AG, Wong JS, Punglia RS, Shiloh RY, Warren LEG, Krishnan MS, Phillips J, Pretz J, Jimenez R, Macausland S, Pashtan I, Andrews C, Isakoff SJ, Winer EP, Tolaney SM. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: 45-52. PMID: 33713742, DOI: 10.1016/j.ijrobp.2021.03.002.
  • Tumor subtypes and survival in male breast cancer.Leone J, Freedman RA, Lin NU, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Leone JP. Tumor subtypes and survival in male breast cancer. Breast Cancer Research And Treatment 2021, 188: 695-702. PMID: 33770314, DOI: 10.1007/s10549-021-06182-y.
  • Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19.Klein IA, Rosenberg SM, Reynolds KL, Zubiri L, Rosovsky R, Piper-Vallillo AJ, Gao X, Boland G, Bardia A, Gaither R, Freeman H, Kirkner GJ, Rhee C, Klompas M, Baker MA, Wadleigh M, Winer EP, Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. The Oncologist 2021, 26: 685-693. PMID: 33856099, PMCID: PMC8251362, DOI: 10.1002/onco.13794.
  • Factors associated with late risks of breast cancer-specific mortality in the SEER registry.Leone JP, Vallejo CT, Hassett MJ, Leone J, Graham N, Tayob N, Freedman RA, Tolaney SM, Leone BA, Winer EP, Lin NU. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Research And Treatment 2021, 189: 203-212. PMID: 33893907, PMCID: PMC8302525, DOI: 10.1007/s10549-021-06233-4.
  • Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. The Oncologist 2021, 26: e1483. PMID: 33978307, PMCID: PMC8342577, DOI: 10.1002/onco.13809.
  • Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance).Ligibel JA, Huebner L, Rugo HS, Burstein HJ, Toppmeyer DL, Anders CK, Ma C, Barry WT, Suman V, Carey LA, Partridge AH, Hudis CA, Winer EP. Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectrum 2021, 5 PMID: 33981951, PMCID: PMC8103727, DOI: 10.1093/jncics/pkab025.
  • Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2021, 39: 2720-2731. PMID: 34003702, DOI: 10.1200/JCO.20.03613.
  • Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. Journal Of The National Cancer Institute 2021 PMID: 34010423, PMCID: PMC8634483, DOI: 10.1093/jnci/djab095.
  • PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Winer EP, Kockx MM, Peeters D, Chui SY, Lin JC, Duc AN, Viale G, Molinero L, Emens LA. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. Journal Of The National Cancer Institute 2021 PMID: 34097070, PMCID: PMC8634452, DOI: 10.1093/jnci/djab108.
  • Correction to: Factors associated with late risks of breast cancer‑specific mortality in the SEER registry.Leone JP, Vallejo CT, Hassett MJ, Leone J, Graham N, Tayob N, Freedman RA, Tolaney SM, Leone BA, Winer EP, Lin NU. Correction to: Factors associated with late risks of breast cancer‑specific mortality in the SEER registry. Breast Cancer Research And Treatment 2021, 189: 305. PMID: 34231078, PMCID: PMC8302547, DOI: 10.1007/s10549-021-06268-7.
  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2021, 32: 1216-1235. PMID: 34242744, DOI: 10.1016/j.annonc.2021.06.023.
  • First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2021, 32: 983-993. PMID: 34272041, DOI: 10.1016/j.annonc.2021.05.355.
  • Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.Bayani J, Poncet C, Crozier C, Neven A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Hilbers F, Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, Schröder C, Rubio IT, Ruddy KJ, van Asperen C, Van Den Weyngaert D, van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Giordano SH, Cardoso F, Bartlett JMS. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. NPJ Breast Cancer 2021, 7: 98. PMID: 34312396, PMCID: PMC8313692, DOI: 10.1038/s41523-021-00301-0.
  • Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993.Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2021, 32: 1308. PMID: 34353668, DOI: 10.1016/j.annonc.2021.07.013.
  • Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, Garber JE, Ellisen LW, Winer EP, Goss PE, Yeap BY, Chabner BA, Isakoff SJ. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Research And Treatment 2021, 189: 641-651. PMID: 34417675, DOI: 10.1007/s10549-021-06292-7.
  • Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SM. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer 2021, 7: 110. PMID: 34433812, PMCID: PMC8387440, DOI: 10.1038/s41523-021-00287-9.
  • Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NU. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. The Oncologist 2021, 26: 927-933. PMID: 34472667, PMCID: PMC8571744, DOI: 10.1002/onco.13960.
  • How we treat HER2-positive brain metastases.Stavrou E, Winer EP, Lin NU. How we treat HER2-positive brain metastases. ESMO Open 2021, 6: 100256. PMID: 34482180, PMCID: PMC8424223, DOI: 10.1016/j.esmoop.2021.100256.
  • Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2021, 32: 1650. PMID: 34740469, DOI: 10.1016/j.annonc.2021.10.002.
  • Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, 40: 282-293. PMID: 34874182, DOI: 10.1200/JCO.21.02554.
  • Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele A. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, 40: 449-458. PMID: 34995105, DOI: 10.1200/JCO.21.01918.
  • The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2022, 28: 1258-1267. PMID: 35046057, DOI: 10.1158/1078-0432.CCR-21-3418.
  • Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings.Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Lederman RI, Frank E, Sohl JJ, Stadler ZK, Erick TK, Peppercorn J, Winer EP, Silverman SG, Come SE, Lin NU. Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Research And Treatment 2022, 192: 201-210. PMID: 35066788, DOI: 10.1007/s10549-021-06494-z.
  • Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea A, Swisher EM, Matulonis UA, Wulf GM, Mayer EL. Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2022, 28: 1493-1499. PMID: 35149538, PMCID: PMC9066379, DOI: 10.1158/1078-0432.CCR-21-3045.
  • Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. The New England Journal Of Medicine 2022, 386: 942-950. PMID: 35263519, DOI: 10.1056/NEJMoa2114663.
  • GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays.Li A, Liu Z, Lezon-Geyda K, Sarkar S, Lannin D, Schulz V, Krop I, Winer E, Harris L, Tuck D. GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Research 2011, 39: 4928-41. PMID: 21398628, PMCID: PMC3130254, DOI: 10.1093/nar/gkr014.
  • Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design.Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer 2017, 3: 37. PMID: 28948213, PMCID: PMC5608692, DOI: 10.1038/s41523-017-0040-8.
  • A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 3234-41. PMID: 22649126, DOI: 10.1200/JCO.2011.40.5902.
  • Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.Varadan V, Gilmore H, Miskimen KL, Tuck DP, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris L. Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 3249-59. PMID: 26842237, PMCID: PMC5439498, DOI: 10.1158/1078-0432.CCR-15-2021.
  • Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell 2016, 29: 255-269. PMID: 26977878, PMCID: PMC4794996, DOI: 10.1016/j.ccell.2016.02.006.
  • Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglehart JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine 2016, 22: 723-6. PMID: 27270588, PMCID: PMC4938731, DOI: 10.1038/nm.4120.
  • In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings 2015, 90: 996-1000. PMID: 26211600, PMCID: PMC5365030, DOI: 10.1016/j.mayocp.2015.06.001.
  • Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008, 113: 2638-45. PMID: 18833576, PMCID: PMC2835546, DOI: 10.1002/cncr.23930.
  • Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 3430-6. PMID: 19470942, PMCID: PMC4979079, DOI: 10.1200/JCO.2008.18.4085.
  • PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Research And Treatment 2013, 138: 457-66. PMID: 23423445, PMCID: PMC3608881, DOI: 10.1007/s10549-013-2416-2.
  • Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry LN, Tolaney S, Dang CT, Krop IE, Harris LN, Berry DA, Mardis ER, Winer EP, Hudis CA, Carey LA, Perou CM. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 5292-5304. PMID: 30037817, PMCID: PMC6214737, DOI: 10.1158/1078-0432.CCR-17-3431.
  • Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 8453-60. PMID: 16293876, DOI: 10.1200/JCO.2005.02.5460.
  • Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study.Ligibel JA, Dillon D, Giobbie-Hurder A, McTiernan A, Frank E, Cornwell M, Pun M, Campbell N, Dowling RJO, Chang MC, Tolaney S, Chagpar AB, Yung RL, Freedman RA, Dominici LS, Golshan M, Rhei E, Taneja K, Huang Y, Brown M, Winer EP, Jeselsohn R, Irwin ML. Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 5398-5406. PMID: 31018921, DOI: 10.1158/1078-0432.CCR-18-3143.
  • Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors.Meyerhardt JA, Irwin ML, Jones LW, Zhang S, Campbell N, Brown JC, Pollak M, Sorrentino A, Cartmel B, Harrigan M, Tolaney SM, Winer E, Ng K, Abrams T, Fuchs CS, Sanft T, Douglas PS, Hu F, Ligibel JA. Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. JNCI Cancer Spectrum 2020, 4: pkz096. PMID: 32090192, PMCID: PMC7025659, DOI: 10.1093/jncics/pkz096.
  • TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 1539-1548. PMID: 32097092, PMCID: PMC8462533, DOI: 10.1200/JCO.19.03292.
  • Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 2610-2619. PMID: 32468955, PMCID: PMC7403000, DOI: 10.1200/JCO.20.00775.
  • Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial.Brown JC, Zhang S, Ligibel JA, Irwin ML, Jones LW, Campbell N, Pollak MN, Sorrentino A, Cartmel B, Harrigan M, Tolaney SM, Winer EP, Ng K, Abrams TA, Sanft T, Douglas PS, Hu FB, Fuchs CS, Meyerhardt JA. Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. Cancer Prevention Research (Philadelphia, Pa.) 2020, 13: 1055-1062. PMID: 32859615, PMCID: PMC7718298, DOI: 10.1158/1940-6207.CAPR-20-0188.
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.Peppercorn J, Herndon J, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer 2005, 104: 1580-9. PMID: 16118805, DOI: 10.1002/cncr.21363.
  • Ovarian suppression for breast cancer: an effective treatment in search of a home.Krop IE, Winer EP. Ovarian suppression for breast cancer: an effective treatment in search of a home. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 5869-72. PMID: 16087947, DOI: 10.1200/JCO.2005.06.002.
  • Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? Journal Of Surgical Oncology 2007, 96: 474-80. PMID: 17640031, DOI: 10.1002/jso.20856.
  • Ten years of HER2-directed therapy: still questions after all these years.Krop IE, Winer EP. Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Research And Treatment 2009, 113: 207-9. PMID: 18463974, DOI: 10.1007/s10549-008-0041-2.
  • Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJ. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2012, 23: 93-97. PMID: 21531783, PMCID: PMC3276325, DOI: 10.1093/annonc/mdr061.
  • A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE, Partridge AH, Eisenberg E, Winer EP, Lin NU. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clinical Breast Cancer 2011, 11: 376-83. PMID: 21697017, PMCID: PMC3773692, DOI: 10.1016/j.clbc.2011.03.024.
  • Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29: 3126-32. PMID: 21730275, PMCID: PMC3157979, DOI: 10.1200/JCO.2010.32.2321.
  • The ethical use of mandatory research biopsies.Olson EM, Lin NU, Krop IE, Winer EP. The ethical use of mandatory research biopsies. Nature Reviews. Clinical Oncology 2011, 8: 620-5. PMID: 21808265, PMCID: PMC3632075, DOI: 10.1038/nrclinonc.2011.114.
  • Further progress in HER2-directed therapy.Krop I, Winer EP. Further progress in HER2-directed therapy. The Lancet. Oncology 2012, 13: 2-3. PMID: 22225715, DOI: 10.1016/S1470-2045(11)70388-6.
  • A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, Fornier M, Winer EP, Bunnell C, Krop IE. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 1841-1847. PMID: 23559151, PMCID: PMC3690910, DOI: 10.1093/annonc/mdt121.
  • A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research And Treatment 2013, 139: 403-10. PMID: 23645007, DOI: 10.1007/s10549-013-2551-9.
  • Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clinical Breast Cancer 2013, 13: 254-63. PMID: 23829891, PMCID: PMC4084778, DOI: 10.1016/j.clbc.2013.02.010.
  • Pertuzumab: optimizing HER2 blockade.Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 5552-6. PMID: 23942091, DOI: 10.1158/1078-0432.CCR-13-0518.
  • Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.Kansal KJ, Dominici LS, Tolaney SM, Isakoff SJ, Smith BL, Jiang W, Brock JE, Winer EP, Krop IE, Golshan M. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction. Breast Cancer Research And Treatment 2013, 141: 255-9. PMID: 24026859, DOI: 10.1007/s10549-013-2682-z.
  • Prospective clinical experience with research biopsies in breast cancer patients.Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Research And Treatment 2013, 142: 203-9. PMID: 24113744, PMCID: PMC3825285, DOI: 10.1007/s10549-013-2717-5.
  • Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 15-20. PMID: 24135146, DOI: 10.1158/1078-0432.CCR-13-0541.
  • Author's reply: Use of discard pleural fluid in molecular research.Olson EM, Lin NU, Krop IE, Winer EP. Author's reply: Use of discard pleural fluid in molecular research. Nature Reviews. Clinical Oncology 2012, 9 PMID: 24222788, PMCID: PMC3821068, DOI: 10.1038/nrclinonc.2011.114-c2.
  • A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Medicine 2014, 3: 293-9. PMID: 24464780, PMCID: PMC3987079, DOI: 10.1002/cam4.164.
  • Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 2078-99. PMID: 24799465, PMCID: PMC6076031, DOI: 10.1200/JCO.2013.54.0948.
  • Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 2100-8. PMID: 24799487, PMCID: PMC6366342, DOI: 10.1200/JCO.2013.54.0955.
  • Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M, Ciruelos E, Garcia AA, Campana F, Wu B, Xu Y, Jiang J, Winer E, Krop I. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Research And Treatment 2015, 149: 151-61. PMID: 25537644, DOI: 10.1007/s10549-014-3248-4.
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The New England Journal Of Medicine 2015, 372: 134-41. PMID: 25564897, PMCID: PMC4313867, DOI: 10.1056/NEJMoa1406281.
  • SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. Journal Of The National Cancer Institute 2015, 107 PMID: 25688104, PMCID: PMC4342675, DOI: 10.1093/jnci/dju493.
  • Personalization of loco-regional care for primary breast cancer patients (part 1).Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS. Personalization of loco-regional care for primary breast cancer patients (part 1). Future Oncology (London, England) 2015, 11: 1297-300. PMID: 25952777, DOI: 10.2217/fon.15.65.
  • Personalization of loco-regional care for primary breast cancer patients (part 2).Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS. Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncology (London, England) 2015, 11: 1301-5. PMID: 25952778, DOI: 10.2217/fon.15.66.
  • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Research And Treatment 2015, 151: 589-96. PMID: 25981899, PMCID: PMC5057177, DOI: 10.1007/s10549-015-3426-z.
  • Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Investigational New Drugs 2015, 33: 1108-14. PMID: 26123926, PMCID: PMC4608248, DOI: 10.1007/s10637-015-0269-8.
  • Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 2623-31. PMID: 26169615, PMCID: PMC4534525, DOI: 10.1200/JCO.2014.60.0353.
  • PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 2016, 35: 3607-12. PMID: 26500061, PMCID: PMC4846581, DOI: 10.1038/onc.2015.406.
  • Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 542-9. PMID: 26527775, PMCID: PMC4980567, DOI: 10.1200/JCO.2015.62.1268.
  • Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology 2016, 2: 29-36. PMID: 26539793, PMCID: PMC5654518, DOI: 10.1001/jamaoncol.2015.3709.
  • Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proceedings Of The National Academy Of Sciences Of The United States Of America 2015, 112: 14325-30. PMID: 26578779, PMCID: PMC4655544, DOI: 10.1073/pnas.1518808112.
  • PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJ. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene 2016, 35: 2961-70. PMID: 26640141, PMCID: PMC4896860, DOI: 10.1038/onc.2015.377.
  • Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer E, Letai A, Barry WT, Carroll JS, Long H, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 2016, 529: 413-417. PMID: 26735014, PMCID: PMC4854653, DOI: 10.1038/nature16508.
  • Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 945-52. PMID: 26834058, PMCID: PMC5070554, DOI: 10.1200/JCO.2015.63.0343.
  • Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology 2016, 17: 811-821. PMID: 27155741, PMCID: PMC5524539, DOI: 10.1016/S1470-2045(16)00106-6.
  • CDK4/6 inhibition triggers anti-tumour immunity.Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ. CDK4/6 inhibition triggers anti-tumour immunity. Nature 2017, 548: 471-475. PMID: 28813415, PMCID: PMC5570667, DOI: 10.1038/nature23465.
  • Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 543-553. PMID: 29298117, PMCID: PMC5815405, DOI: 10.1200/JCO.2017.76.0033.
  • Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 2736-2740. PMID: 29939838, DOI: 10.1200/JCO.2018.79.2697.
  • Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, Levinson J, Modi S, Patt DA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 2804-2807. PMID: 29939840, DOI: 10.1200/JCO.2018.79.2713.
  • 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2018, 29: 1634-1657. PMID: 30032243, PMCID: PMC7360146, DOI: 10.1093/annonc/mdy192.
  • Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer.Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, Brown M, Jeselsohn R. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer 2018, 4: 22. PMID: 30083595, PMCID: PMC6072793, DOI: 10.1038/s41523-018-0075-5.
  • TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 714-722. PMID: 30721110, PMCID: PMC6424139, DOI: 10.1200/JCO.2018.78.7986.
  • The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 575-581. PMID: 30753274, PMCID: PMC8033534, DOI: 10.1093/annonc/mdz047.
  • TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 1081-1089. PMID: 30860945, PMCID: PMC6494354, DOI: 10.1200/JCO.18.01511.
  • Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 1868-1875. PMID: 30939096, PMCID: PMC7587424, DOI: 10.1200/JCO.19.00066.
  • Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research And Treatment 2019, 176: 303-310. PMID: 31004299, DOI: 10.1007/s10549-019-05238-4.
  • The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 4644-4655. PMID: 31061067, PMCID: PMC6677598, DOI: 10.1158/1078-0432.CCR-19-0173.
  • Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clinical Breast Cancer 2020, 20: 145-151.e2. PMID: 31558424, PMCID: PMC7035200, DOI: 10.1016/j.clbc.2019.07.011.
  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England Journal Of Medicine 2020, 382: 597-609. PMID: 31825569, DOI: 10.1056/NEJMoa1914609.
  • Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Van Allen EM, Tolaney SM. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 2565-2572. PMID: 32019858, PMCID: PMC7269810, DOI: 10.1158/1078-0432.CCR-19-3507.
  • A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.Barroso-Sousa R, Krop IE, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson ET, Pastorello RG, Winer EP, Mittendorf EA, Bellon JR, Schoenfeld JD, Tolaney SM. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer 2020, 20: 238-245. PMID: 32113750, DOI: 10.1016/j.clbc.2020.01.012.
  • Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, Leong KW, Hughes ME, Rosenberg SM, Collins LC, Miller KD, Blumenstiel B, Trippa L, Cibulskis C, Neuberg DS, DeFelice M, Freeman SS, Lennon NJ, Wagle N, Ha G, Stover DG, Choudhury AD, Getz G, Winer EP, Meyerson M, Lin NU, Krop I, Love JC, Makrigiorgos GM, Partridge AH, Mayer EL, Golub TR, Adalsteinsson VA. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 2556-2564. PMID: 32170028, PMCID: PMC7654718, DOI: 10.1158/1078-0432.CCR-19-3005.
  • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2020, 31: 590-598. PMID: 32245699, PMCID: PMC7946408, DOI: 10.1016/j.annonc.2020.02.008.
  • Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.Metzger Filho O, Leone JP, Li T, Tan-Wasielewski Z, Trippa L, Barry WT, Younger J, Lawler E, Walker L, Freedman RA, Tolaney SM, Krop I, Winer EP, Lin NU. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2020, 31: 1231-1239. PMID: 32461105, DOI: 10.1016/j.annonc.2020.05.014.
  • TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2020, 31: 1518-1525. PMID: 32798689, PMCID: PMC8437015, DOI: 10.1016/j.annonc.2020.08.2064.
  • Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncology 2020, 6: 1598-1605. PMID: 32880602, PMCID: PMC7489368, DOI: 10.1001/jamaoncol.2020.3524.
  • Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precision Oncology 2019, 3 PMID: 32923853, PMCID: PMC7446367, DOI: 10.1200/PO.19.00087.
  • A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.Krop I, Abramson VG, Colleoni M, Traina TA, Holmes FA, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg LS, Chan SY, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau ME, Markova D, Tarazi JC, Zhu Z, O'Brien T, Kelly C, Winer EP, Yardley D. A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 6149-6157. PMID: 32988969, DOI: 10.1158/1078-0432.CCR-20-1693.
  • Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 4184-4193. PMID: 33095682, PMCID: PMC7723687, DOI: 10.1200/JCO.20.01276.
  • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 4274-4282. PMID: 33119476, DOI: 10.1200/JCO.20.02151.
  • Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, Gavilá J, Serra V, Prat A, Paré L, Céliz P, Villagrasa P, Li Y, Savoie J, Xu Z, Arteaga CL, Krop IE, Solit DB, Mills GB, Cantley LC, Winer EP, Lin NU, Rodon J. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research : BCR 2020, 22: 120. PMID: 33138866, PMCID: PMC7607628, DOI: 10.1186/s13058-020-01354-y.
  • Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, Younger J, Pinho MC, Sorensen AG, Gerstner ER, Harris G, Krop IE, Morganstern D, Sohl J, Hu J, Kasparian E, Winer EP, Lin NU. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Research : BCR 2020, 22: 131. PMID: 33256829, PMCID: PMC7706261, DOI: 10.1186/s13058-020-01372-w.
  • Genomic Characterization of de novo Metastatic Breast Cancer.Garrido-Castro AC, Spurr LF, Hughes ME, Li YY, Cherniack AD, Kumari P, Lloyd MR, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Jain E, Files J, Mohammed-Abreu A, Krevalin M, MacKichan C, Barry WT, Guo H, Xia D, Cerami E, Rollins BJ, MacConaill LE, Lindeman NI, Krop IE, Johnson BE, Wagle N, Winer EP, Dillon DA, Lin NU. Genomic Characterization of de novo Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 1105-1118. PMID: 33293374, PMCID: PMC7887078, DOI: 10.1158/1078-0432.CCR-20-1720.
  • CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity.Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, Meyer CA, Gilan O, Bell CC, Korthauer KD, Giambartolomei C, Pasaniuc B, Seo JH, Freedman ML, Ma C, Ellis MJ, Krop I, Winer E, Letai A, Brown M, Dawson MA, Long HW, Zhao JJ, Goel S. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer 2021, 2: 34-48. PMID: 33997789, PMCID: PMC8115221, DOI: 10.1038/s43018-020-00135-y.
  • High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. Journal Of The National Cancer Institute 1992, 84: 1811-6. PMID: 1359155, DOI: 10.1093/jnci/84.23.1811.
  • Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RL, Crawford J, Herndon JE, Trump DL. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Research 1992, 52: 2456-9. PMID: 1533174.
  • Improved survival in advanced Hodgkin's disease with the use of combined modality therapy.Brizel DM, Winer EP, Prosnitz LR, Scott J, Crawford J, Moore JO, Gockerman JP. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. International Journal Of Radiation Oncology, Biology, Physics 1990, 19: 535-42. PMID: 2211201, DOI: 10.1016/0360-3016(90)90478-3.
  • The use of adjuvant chemotherapy for breast cancer in a community practice.Rosenberg A, Winer EP, Cadman E. The use of adjuvant chemotherapy for breast cancer in a community practice. Connecticut Medicine 1985, 49: 281-5. PMID: 3839177.
  • Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.Winer EP, Chu L, Spicer DV. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Seminars In Oncology 1995, 22: 72-8; discussion 78-9. PMID: 7740337.
  • Quality-of-life research in patients with breast cancer.Winer EP. Quality-of-life research in patients with breast cancer. Cancer 1994, 74: 410-5. PMID: 8004614, DOI: 10.1002/cncr.2820741328.
  • Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1994, 12: 1754-63. PMID: 8083697, DOI: 10.1200/JCO.1994.12.9.1754.
  • Quality of life after bone marrow transplantation.Winer EP, Sutton LM. Quality of life after bone marrow transplantation. Oncology (Williston Park, N.Y.) 1994, 8: 19-27; discussion 27-8, 31. PMID: 8123445.
  • Why women gain weight with adjuvant chemotherapy for breast cancer.Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1993, 11: 1418-29. PMID: 8315439, DOI: 10.1200/JCO.1993.11.7.1418.
  • Silicone controversy: a survey of women with breast cancer and silicone implants.Winer EP, Fee-Fulkerson K, Fulkerson CC, Georgiade G, Catoe KE, Conaway M, Brunatti C, Holmes V, Rimer BK. Silicone controversy: a survey of women with breast cancer and silicone implants. Journal Of The National Cancer Institute 1993, 85: 1407-11. PMID: 8350364, DOI: 10.1093/jnci/85.17.1407.
  • Factors contributing to patient satisfaction with breast reconstruction using silicone gel implants.Fee-Fulkerson K, Conaway MR, Winer EP, Fulkerson CC, Rimer BK, Georgiade G. Factors contributing to patient satisfaction with breast reconstruction using silicone gel implants. Plastic And Reconstructive Surgery 1996, 97: 1420-6. PMID: 8643726, DOI: 10.1097/00006534-199606000-00016.
  • Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy.Demark-Wahnefried W, Hars V, Conaway MR, Havlin K, Rimer BK, McElveen G, Winer EP. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. The American Journal Of Clinical Nutrition 1997, 65: 1495-501. PMID: 9129482, DOI: 10.1093/ajcn/65.5.1495.
  • Weight gain in women diagnosed with breast cancer.Demark-Wahnefried W, Rimer BK, Winer EP. Weight gain in women diagnosed with breast cancer. Journal Of The American Dietetic Association 1997, 97: 519-26, 529; quiz 527-8. PMID: 9145091, DOI: 10.1016/s0002-8223(97)00133-8.
  • A review of hereditary breast cancer: from screening to risk factor modification.Warmuth MA, Sutton LM, Winer EP. A review of hereditary breast cancer: from screening to risk factor modification. The American Journal Of Medicine 1997, 102: 407-15. PMID: 9217624, DOI: 10.1016/s0002-9343(97)00093-4.
  • Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial.Sutton LM, Warmuth MA, Petros WP, Winer EP. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemotherapy And Pharmacology 1997, 40: 335-41. PMID: 9225952, DOI: 10.1007/s002800050666.
  • Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. The Journal Of Infusional Chemotherapy 1996, 6: 211-6. PMID: 9229318.
  • Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1998, 16: 1380-7. PMID: 9552041, DOI: 10.1200/JCO.1998.16.4.1380.
  • Cancer pain survey: patient-centered issues in control.Thomason TE, McCune JS, Bernard SA, Winer EP, Tremont S, Lindley CM. Cancer pain survey: patient-centered issues in control. Journal Of Pain And Symptom Management 1998, 15: 275-84. PMID: 9654832, DOI: 10.1016/s0885-3924(98)00016-5.
  • Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1998, 16: 2417-25. PMID: 9667259, DOI: 10.1200/JCO.1998.16.7.2417.
  • Overestimation of hereditary breast cancer risk.Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Overestimation of hereditary breast cancer risk. Annals Of Surgery 1998, 228: 375-84. PMID: 9742920, PMCID: PMC1191495, DOI: 10.1097/00000658-199809000-00010.
  • Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey.Warmuth MA, Bowen G, Prosnitz LR, Chu L, Broadwater G, Peterson B, Leight G, Winer EP. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer 1998, 83: 1362-8. PMID: 9762937, DOI: 10.1002/(sici)1097-0142(19981001)83:7<1362::aid-cncr13>3.0.co;2-2.
  • Oral 5-FU analogues in the treatment of breast cancer.Bunnell CA, Winer EP. Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park, N.Y.) 1998, 12: 39-43. PMID: 9830624.
  • Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemotherapy And Pharmacology 1999, 43: 68-72. PMID: 9923543, DOI: 10.1007/s002800050864.
  • Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1999, 17: 1040-6. PMID: 10071299, DOI: 10.1200/JCO.1999.17.3.1040.
  • Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis.Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1999, 17: 1465-73. PMID: 10334532, DOI: 10.1200/JCO.1999.17.5.1465.
  • Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.Winer EP, Lindley C, Hardee M, Sawyer WT, Brunatti C, Borstelmann NA, Peters W. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psycho-oncology 1999, 8: 167-76. PMID: 10335560, DOI: 10.1002/(SICI)1099-1611(199903/04)8:2<167::AID-PON354>3.0.CO;2-S.
  • Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Medical Decision Making : An International Journal Of The Society For Medical Decision Making 1998, 18: 365-75. PMID: 10372578, DOI: 10.1177/0272989X9801800402.
  • Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1999, 17: 52-63. PMID: 10458218, DOI: 10.1200/JCO.1999.17.1.52.
  • American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1999, 17: 3333-55. PMID: 10506637, DOI: 10.1200/JCO.1999.17.10.3333.
  • Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1999, 17: 2506-13. PMID: 10561316, DOI: 10.1200/JCO.1999.17.8.2506.
  • Phase I study of Doxil and vinorelbine in metastatic breast cancer.Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 1999, 10: 1113-6. PMID: 10572612, DOI: 10.1023/a:1008323200102.
  • A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, Vogelzang NJ. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000, 88: 825-34. PMID: 10679652.
  • Docetaxel administered on a weekly basis for metastatic breast cancer.Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2000, 18: 1212-9. PMID: 10715290, DOI: 10.1200/JCO.2000.18.6.1212.
  • Testing for hereditary breast and ovarian cancer in the southeastern United States.Miron A, Schildkraut JM, Rimer BK, Winer EP, Sugg Skinner C, Futreal PA, Culler D, Calingaert B, Clark S, Kelly Marcom P, Iglehart JD. Testing for hereditary breast and ovarian cancer in the southeastern United States. Annals Of Surgery 2000, 231: 624-34. PMID: 10767783, PMCID: PMC1421049, DOI: 10.1097/00000658-200005000-00002.
  • Phase II evaluation of thalidomide in patients with metastatic breast cancer.Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Phase II evaluation of thalidomide in patients with metastatic breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2000, 18: 2710-7. PMID: 10894870, DOI: 10.1200/JCO.2000.18.14.2710.
  • Primary care for survivors of breast cancer.Burstein HJ, Winer EP. Primary care for survivors of breast cancer. The New England Journal Of Medicine 2000, 343: 1086-94. PMID: 11027744, DOI: 10.1056/NEJM200010123431506.
  • NCCN Practice Guidelines for Breast Cancer.Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A. NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park, N.Y.) 2000, 14: 33-49. PMID: 11195418.
  • Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K, Rimer BK. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2001, 19: 2381-9. PMID: 11331316, DOI: 10.1200/JCO.2001.19.9.2381.
  • Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2001, 19: 2722-30. PMID: 11352965, DOI: 10.1200/JCO.2001.19.10.2722.
  • New cytotoxic agents and schedules for advanced breast cancer.Burstein HJ, Bunnell CA, Winer EP. New cytotoxic agents and schedules for advanced breast cancer. Seminars In Oncology 2001, 28: 344-58. PMID: 11498829, DOI: 10.1016/s0093-7754(01)90129-0.
  • Liposomal anthracyclines for breast cancer.Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Seminars In Oncology 2001, 28: 32-40. PMID: 11552228.
  • Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ.Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP. Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. Journal Of Women's Health & Gender-based Medicine 2001, 10: 589-98. PMID: 11559456, DOI: 10.1089/15246090152543175.
  • New combinations with Herceptin in metastatic breast cancer.Winer EP, Burstein HJ. New combinations with Herceptin in metastatic breast cancer. Oncology 2001, 61 Suppl 2: 50-7. PMID: 11694788, DOI: 10.1159/000055402.
  • Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. Journal Of The National Cancer Institute. Monographs 2001, 135-42. PMID: 11773307, DOI: 10.1093/oxfordjournals.jncimonographs.a003451.
  • Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94: 25-36. PMID: 11815957, DOI: 10.1002/cncr.10201.
  • Adherence to therapy with oral antineoplastic agents.Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. Journal Of The National Cancer Institute 2002, 94: 652-61. PMID: 11983753, DOI: 10.1093/jnci/94.9.652.
  • 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 2895-903. PMID: 12065567, DOI: 10.1200/JCO.2002.04.178.
  • Informing clinical trial participants about study results.Partridge AH, Winer EP. Informing clinical trial participants about study results. JAMA 2002, 288: 363-5. PMID: 12117402, DOI: 10.1001/jama.288.3.363.
  • Trastuzumab/chemotherapy combinations in metastatic breast cancer.Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Seminars In Oncology 2002, 29: 38-43. PMID: 12138396, DOI: 10.1053/sonc.2002.34054.
  • American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 3317-27. PMID: 12149306, DOI: 10.1200/JCO.2002.06.020.
  • American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 3328-43. PMID: 12149307, DOI: 10.1200/JCO.2002.06.029.
  • Lumping versus splitting: the splitters take this round.Bunnell CA, Winer EP. Lumping versus splitting: the splitters take this round. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 3576-7. PMID: 12202656, DOI: 10.1200/JCO.2002.06.157.
  • Pre-counseling education materials for BRCA testing: does tailoring make a difference?Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genetic Testing 2002, 6: 93-105. PMID: 12215248, DOI: 10.1089/10906570260199348.
  • Complementary and alternative medicine use among women with breast cancer.DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 34S-8S. PMID: 12235222.
  • Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 46-53. PMID: 12506169, DOI: 10.1200/JCO.2003.03.124.
  • Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 443S-6S. PMID: 12538498.
  • Clinical differences among the aromatase inhibitors.Ligibel JA, Winer EP. Clinical differences among the aromatase inhibitors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 473S-9S. PMID: 12538503.
  • Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 602-6. PMID: 12586795, DOI: 10.1200/JCO.2003.07.071.
  • Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 999-1006. PMID: 12637463, DOI: 10.1200/JCO.2003.05.068.
  • Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 1007-14. PMID: 12637464, DOI: 10.1200/JCO.2003.06.108.
  • Do patients participating in clinical trials want to know study results?Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Do patients participating in clinical trials want to know study results? Journal Of The National Cancer Institute 2003, 95: 491-2. PMID: 12644548, DOI: 10.1093/jnci/95.6.491.
  • Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 1431-9. PMID: 12668651, DOI: 10.1200/JCO.2003.09.081.
  • Quality of non-breast cancer health maintenance among elderly breast cancer survivors.Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 1447-51. PMID: 12697865, DOI: 10.1200/JCO.2003.03.060.
  • American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 2597-9. PMID: 12732612, DOI: 10.1200/JCO.2003.04.596.
  • Hormonal therapy in postmenopausal women with breast cancer.Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology 2003, 64: 289-99. PMID: 12759523, DOI: 10.1159/000070284.
  • Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97: 2972-7. PMID: 12784331, DOI: 10.1002/cncr.11436.
  • Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.Bluman LG, Rimer BK, Regan Sterba K, Lancaster J, Clark S, Borstelmann N, Iglehart JD, Winer EP. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psycho-oncology 2003, 12: 410-27. PMID: 12833555, DOI: 10.1002/pon.653.
  • Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Research And Treatment 2003, 79: 391-7. PMID: 12846423, DOI: 10.1023/a:1024038127156.
  • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 2889-95. PMID: 12885806, DOI: 10.1200/JCO.2003.02.018.
  • Amifostine and chemoradiation therapy: ASCO responds.Schuchter L, Meropol NJ, Winer EP, Hensley ML, Somerfield MR. Amifostine and chemoradiation therapy: ASCO responds. The Lancet. Oncology 2003, 4: 593. PMID: 14554234, DOI: 10.1016/s1470-2045(03)01216-6.
  • Follow-up care of breast cancer survivors.Partridge AH, Winer EP, Burstein HJ. Follow-up care of breast cancer survivors. Seminars In Oncology 2003, 30: 817-25. PMID: 14663782, DOI: 10.1053/j.seminoncol.2003.08.026.
  • Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer.Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 4532-9. PMID: 14673040, DOI: 10.1200/JCO.2003.05.131.
  • HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2004, 22: 854-63. PMID: 14990641, DOI: 10.1200/JCO.2004.04.158.
  • Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants.Partridge AH, Hackett N, Blood E, Gelman R, Joffe S, Bauer-Wu S, Knudsen K, Emmons K, Collyar D, Schilsky RL, Winer EP. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. Journal Of The National Cancer Institute 2004, 96: 629-32. PMID: 15100341, DOI: 10.1093/jnci/djh096.
  • Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2004, 22: 2061-8. PMID: 15169793, DOI: 10.1200/JCO.2004.08.048.
  • New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors.Lin NU, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Research : BCR 2004, 6: 204-10. PMID: 15318926, PMCID: PMC549180, DOI: 10.1186/bcr919.
  • CNS metastases in breast cancer.Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2004, 22: 3608-17. PMID: 15337811, DOI: 10.1200/JCO.2004.01.175.
  • Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. The New England Journal Of Medicine 2004, 351: 971-7. PMID: 15342805, DOI: 10.1056/NEJMoa040587.
  • Web-based survey of fertility issues in young women with breast cancer.Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP. Web-based survey of fertility issues in young women with breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2004, 22: 4174-83. PMID: 15483028, DOI: 10.1200/JCO.2004.01.159.
  • American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 619-29. PMID: 15545664, DOI: 10.1200/JCO.2005.09.121.
  • Patient utilities for advanced cancer: effect of current health on values.Wittenberg E, Winer EP, Weeks JC. Patient utilities for advanced cancer: effect of current health on values. Medical Care 2005, 43: 173-81. PMID: 15655431, DOI: 10.1097/00005650-200502000-00011.
  • Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer.Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. International Journal Of Radiation Oncology, Biology, Physics 2005, 61: 348-57. PMID: 15667952, DOI: 10.1016/j.ijrobp.2004.06.011.
  • Quality of life issues among women undergoing high-dose chemotherapy for breast cancer.Partridge AH, Bunnell CA, Winer EP. Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Disease 2001, 14: 41-50. PMID: 15687635, DOI: 10.3233/bd-2001-14106.
  • Long-term complications of adjuvant chemotherapy for early stage breast cancer.Partridge AH, Winer EP. Long-term complications of adjuvant chemotherapy for early stage breast cancer. Breast Disease 2004, 21: 55-64. PMID: 15687723, DOI: 10.3233/bd-2004-21108.
  • The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries.Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. Journal Of General Internal Medicine 2005, 20: 38-44. PMID: 15693926, PMCID: PMC1490029, DOI: 10.1111/j.1525-1497.2004.40079.x.
  • Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Seminars In Oncology 2004, 31: 53-90. PMID: 15717738, DOI: 10.1053/j.seminoncol.2004.08.010.
  • The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars In Oncology 2004, 31: 106-46. PMID: 15717740, DOI: 10.1053/j.seminoncol.2004.09.018.
  • HER2 or not HER2: that is the question.Burstein HJ, Winer EP. HER2 or not HER2: that is the question. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 3656-9. PMID: 15738533, DOI: 10.1200/JCO.2005.10.910.
  • Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005, 293: 1073-81. PMID: 15741529, DOI: 10.1001/jama.293.9.1073.
  • Optimizing endocrine therapy for breast cancer.Winer EP. Optimizing endocrine therapy for breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 1609-10. PMID: 15755964, DOI: 10.1200/JCO.2005.01.005.
  • Offering participants results of a clinical trial: sharing results of a negative study.Partridge AH, Wong JS, Knudsen K, Gelman R, Sampson E, Gadd M, Bishop KL, Harris JR, Winer EP. Offering participants results of a clinical trial: sharing results of a negative study. Lancet 2005, 365: 963-4. PMID: 15766998, DOI: 10.1016/S0140-6736(05)71085-0.
  • Fertility after breast cancer: questions abound.Partridge AH, Winer EP. Fertility after breast cancer: questions abound. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 4259-61. PMID: 15824413, DOI: 10.1200/JCO.2005.12.914.
  • Economic outcomes of breast cancer survivorship: CALGB study 79804.Hensley ML, Dowell J, Herndon JE, Winer E, Stark N, Weeks JC, Paskett E. Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Research And Treatment 2005, 91: 153-61. PMID: 15868443, DOI: 10.1007/s10549-004-6497-9.
  • Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 5178-87. PMID: 15998905, DOI: 10.1200/JCO.2005.02.964.
  • Breast cancer.Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. Journal Of The National Comprehensive Cancer Network : JNCCN 2005, 3: 238-89. PMID: 16002000, DOI: 10.6004/jnccn.2005.0015.
  • Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2005, 16: 1772-7. PMID: 16150805, DOI: 10.1093/annonc/mdi371.
  • American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 7703-20. PMID: 16157938, DOI: 10.1200/JCO.2005.08.001.
  • Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret.Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Education And Counseling 2006, 63: 104-9. PMID: 16242898, DOI: 10.1016/j.pec.2005.09.006.
  • Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. International Journal Of Radiation Oncology, Biology, Physics 2006, 64: 496-504. PMID: 16243442, DOI: 10.1016/j.ijrobp.2005.07.975.
  • Standards for follow-up care of patents with breast cancer.Peppercorn J, Partridge A, Burstein HJ, Winer EP. Standards for follow-up care of patents with breast cancer. Breast (Edinburgh, Scotland) 2005, 14: 500-8. PMID: 16288876, DOI: 10.1016/j.breast.2005.09.001.
  • Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 8340-7. PMID: 16293865, DOI: 10.1200/JCO.2005.02.8621.
  • Cancer-related communication between female patients and male partners scale: A pilot study.Kornblith AB, Regan MM, Kim Y, Greer G, Parker B, Bennett S, Winer E. Cancer-related communication between female patients and male partners scale: A pilot study. Psycho-oncology 2006, 15: 780-94. PMID: 16308887, DOI: 10.1002/pon.1004.
  • Dose density in breast cancer: a simple message?Lin NU, Gelman R, Winer EP. Dose density in breast cancer: a simple message? Journal Of The National Cancer Institute 2005, 97: 1712-4. PMID: 16333021, DOI: 10.1093/jnci/dji438.
  • Factors related to underuse of surveillance mammography among breast cancer survivors.Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography among breast cancer survivors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2006, 24: 85-94. PMID: 16382117, DOI: 10.1200/JCO.2005.02.4174.
  • Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.Ligibel JA, Winer EP. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Research : BCR 2005, 7: 255-7. PMID: 16457700, PMCID: PMC1410766, DOI: 10.1186/bcr1347.
  • Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2006, 12: 997s-1000s. PMID: 16467115, DOI: 10.1158/1078-0432.CCR-05-2268.
  • NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Journal Of The National Comprehensive Cancer Network : JNCCN 2006, 4 Suppl 1: S1-26. PMID: 16507275.
  • Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295: 1658-67. PMID: 16609087, PMCID: PMC1459540, DOI: 10.1001/jama.295.14.1658.
  • The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer 2006, 106: 2576-82. PMID: 16703595, DOI: 10.1002/cncr.21919.
  • Cancer and leukemia group B breast committee: decades of progress and plans for the future.Hudis CA, Winer EP. Cancer and leukemia group B breast committee: decades of progress and plans for the future. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2006, 12: 3576s-80s. PMID: 16740788, DOI: 10.1158/1078-0432.CCR-06-9016.
  • Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Research And Treatment 2006, 100: 301-8. PMID: 16773437, DOI: 10.1007/s10549-006-9251-7.
  • HER2 testing in breast cancer: NCCN Task Force report and recommendations.Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM. HER2 testing in breast cancer: NCCN Task Force report and recommendations. Journal Of The National Comprehensive Cancer Network : JNCCN 2006, 4 Suppl 3: S1-22; quiz S23-4. PMID: 16813731.
  • Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules.Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Investigational New Drugs 2007, 25: 161-4. PMID: 16969707, DOI: 10.1007/s10637-006-9007-6.
  • Menopausal-type symptoms in young breast cancer survivors.Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cancer survivors. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2006, 17: 1777-82. PMID: 16971671, DOI: 10.1093/annonc/mdl299.
  • Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2006, 24: 5330-1. PMID: 17114668, DOI: 10.1200/JCO.2006.08.1083.
  • Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research : BCR 2006, 8: R66. PMID: 17129383, PMCID: PMC1797029, DOI: 10.1186/bcr1622.
  • Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psycho-oncology 2007, 16: 895-903. PMID: 17245695, DOI: 10.1002/pon.1146.
  • Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2007, 13: 1198-207. PMID: 17317830, DOI: 10.1158/1078-0432.CCR-06-1304.
  • Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 2007, 109: 1239-46. PMID: 17326054, DOI: 10.1002/cncr.22528.
  • Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Investigational New Drugs 2007, 25: 369-75. PMID: 17345004, DOI: 10.1007/s10637-007-9034-y.
  • Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer.Bullitt E, Lin NU, Ewend MG, Zeng D, Winer EP, Carey LA, Smith JK. Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer. Medical Image Computing And Computer-assisted Intervention : MICCAI ... International Conference On Medical Image Computing And Computer-Assisted Intervention 2006, 9: 561-8. PMID: 17354817, PMCID: PMC2504703, DOI: 10.1007/11866763_69.
  • Brain metastases: the HER2 paradigm.Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2007, 13: 1648-55. PMID: 17363517, DOI: 10.1158/1078-0432.CCR-06-2478.
  • Surveillance testing among survivors of early-stage breast cancer.Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 1074-81. PMID: 17369571, DOI: 10.1200/JCO.2006.08.6876.
  • Invasive breast cancer.Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. Journal Of The National Comprehensive Cancer Network : JNCCN 2007, 5: 246-312. PMID: 17439758, DOI: 10.6004/jnccn.2007.0025.
  • Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. European Journal Of Cancer (Oxford, England : 1990) 2007, 43: 1646-53. PMID: 17512721, DOI: 10.1016/j.ejca.2007.04.006.
  • Local therapy and survival in breast cancer.Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. The New England Journal Of Medicine 2007, 356: 2399-405. PMID: 17554121, DOI: 10.1056/NEJMra065241.
  • Optimal use of aromatase inhibitors: to lead or to follow?Lin NU, Winer EP. Optimal use of aromatase inhibitors: to lead or to follow? Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 2639-41. PMID: 17563391, DOI: 10.1200/JCO.2007.10.9447.
  • Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations.Wray RJ, Stryker JE, Winer E, Demetri G, Emmons KM. Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations. Journal Of Cancer Education : The Official Journal Of The American Association For Cancer Education 2007, 22: 21-4. PMID: 17570804, DOI: 10.1007/BF03174370.
  • Implementing an interdisciplinary governance model in a comprehensive cancer center.Ponte PR, Gross AH, Winer E, Connaughton MJ, Hassinger J. Implementing an interdisciplinary governance model in a comprehensive cancer center. Oncology Nursing Forum 2007, 34: 611-6. PMID: 17573318, DOI: 10.1188/07.ONF.611-616.
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007, 110: 965-72. PMID: 17614302, DOI: 10.1002/cncr.22885.
  • Follow-up care of patients with breast cancer.Tolaney SM, Winer EP. Follow-up care of patients with breast cancer. Breast (Edinburgh, Scotland) 2007, 16 Suppl 2: S45-50. PMID: 17697780, DOI: 10.1016/j.breast.2007.07.005.
  • Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 3699-704. PMID: 17704418, DOI: 10.1200/JCO.2007.10.9710.
  • Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 3797-9. PMID: 17761968, DOI: 10.1200/JCO.2007.11.9529.
  • Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research 2007, 10: 367-76. PMID: 17888101, DOI: 10.1111/j.1524-4733.2007.00190.x.
  • HER2 and response to paclitaxel in node-positive breast cancer.Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. The New England Journal Of Medicine 2007, 357: 1496-506. PMID: 17928597, DOI: 10.1056/NEJMoa071167.
  • Care in the months before death and hospice enrollment among older women with advanced breast cancer.Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Care in the months before death and hospice enrollment among older women with advanced breast cancer. Journal Of General Internal Medicine 2008, 23: 11-8. PMID: 17939006, PMCID: PMC2173914, DOI: 10.1007/s11606-007-0422-y.
  • Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer.Winer EP, Harris JR, Smith BL, D'Alessandro HA, Brachtel EF. Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. The New England Journal Of Medicine 2007, 357: 1640-8. PMID: 17942877, DOI: 10.1056/NEJMcpc079026.
  • Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study.Bullitt E, Lin NU, Smith JK, Zeng D, Winer EP, Carey LA, Lin W, Ewend MG. Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology 2007, 245: 824-30. PMID: 17954616, PMCID: PMC2615672, DOI: 10.1148/radiol.2453061889.
  • Sarcoidosis mimicking metastatic breast cancer.Tolaney SM, Colson YL, Gill RR, Schulte S, Duggan MM, Shulman LN, Winer EP. Sarcoidosis mimicking metastatic breast cancer. Clinical Breast Cancer 2007, 7: 804-10. PMID: 18021484, DOI: 10.3816/CBC.2007.n.044.
  • Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.Come SE, Buzdar AU, Ingle JN, Johnston SRD, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer 2008, 112: 673-678. PMID: 18072254, DOI: 10.1002/cncr.23194.
  • Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2008, 112: 700-709. PMID: 18072256, DOI: 10.1002/cncr.23193.
  • Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 313-25. PMID: 18086794, DOI: 10.1200/JCO.2007.15.4088.
  • Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 556-62. PMID: 18180462, DOI: 10.1200/JCO.2007.11.5451.
  • Heterogeneity of breast cancer and implications of adjuvant chemotherapy.Razzak AR, Lin NU, Winer EP. Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer (Tokyo, Japan) 2008, 15: 31-4. PMID: 18224391, DOI: 10.1007/s12282-007-0007-y.
  • Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Reviews 2008, 34: 223-30. PMID: 18234424, PMCID: PMC2651678, DOI: 10.1016/j.ctrv.2007.11.004.
  • Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 1231-8. PMID: 18250349, PMCID: PMC4048960, DOI: 10.1200/JCO.2007.13.5467.
  • Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.Gralow JR, Zujewski JA, Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 696-7. PMID: 18258975, DOI: 10.1200/JCO.2007.15.9459.
  • Advances in adjuvant endocrine therapy for postmenopausal women.Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 798-805. PMID: 18258989, DOI: 10.1200/JCO.2007.15.0946.
  • Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 814-9. PMID: 18258991, DOI: 10.1200/JCO.2007.15.3510.
  • Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. Journal Of The National Cancer Institute 2008, 100: 243-51. PMID: 18270338, DOI: 10.1093/jnci/djn010.
  • Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 907-12. PMID: 18281663, DOI: 10.1200/JCO.2007.12.7357.
  • Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.Paskett ED, Herndon JE, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA. Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psycho-oncology 2008, 17: 1108-20. PMID: 18314912, PMCID: PMC3930158, DOI: 10.1002/pon.1329.
  • Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.Lin NU, Winer EP. Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 1919-21. PMID: 18332468, DOI: 10.1200/JCO.2007.14.7744.
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 1642-9. PMID: 18375893, DOI: 10.1200/JCO.2007.11.6699.
  • Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research 2008, 11: 213-20. PMID: 18380633, DOI: 10.1111/j.1524-4733.2007.00226.x.
  • Tangential radiotherapy without axillary surgery in early-stage breast cancer: results of a prospective trial.Wong JS, Taghian AG, Bellon JR, Keshaviah A, Smith BL, Winer EP, Silver B, Harris JR. Tangential radiotherapy without axillary surgery in early-stage breast cancer: results of a prospective trial. International Journal Of Radiation Oncology, Biology, Physics 2008, 72: 866-70. PMID: 18394815, DOI: 10.1016/j.ijrobp.2008.01.031.
  • Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 1993-9. PMID: 18421051, PMCID: PMC4524351, DOI: 10.1200/JCO.2007.12.3588.
  • Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. Journal Of The National Cancer Institute 2008, 100: 642-8. PMID: 18445827, PMCID: PMC2864146, DOI: 10.1093/jnci/djn100.
  • Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research And Treatment 2009, 115: 115-21. PMID: 18496750, DOI: 10.1007/s10549-008-0055-9.
  • Fertility and menopausal outcomes in young breast cancer survivors.Partridge AH, Gelber S, Peppercorn J, Ginsburg E, Sampson E, Rosenberg R, Przypyszny M, Winer EP. Fertility and menopausal outcomes in young breast cancer survivors. Clinical Breast Cancer 2008, 8: 65-9. PMID: 18501060, DOI: 10.3816/CBC.2008.n.004.
  • Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 2659-65. PMID: 18509177, PMCID: PMC4830463, DOI: 10.1200/JCO.2007.13.9782.
  • The impact of sharing results of a randomized breast cancer clinical trial with study participants.Partridge AH, Wolff AC, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Research And Treatment 2009, 115: 123-9. PMID: 18543100, DOI: 10.1007/s10549-008-0057-7.
  • Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival.Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Research And Treatment 2009, 115: 7-12. PMID: 18581232, DOI: 10.1007/s10549-008-0101-7.
  • NCCN Task Force Report: breast cancer in the older woman.Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. Journal Of The National Comprehensive Cancer Network : JNCCN 2008, 6 Suppl 4: S1-25; quiz S26-7. PMID: 18597715.
  • Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ.Partridge A, Winer JP, Golshan M, Bellon JR, Blood E, Dees EC, Sampson E, Emmons KM, Winer E. Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clinical Breast Cancer 2008, 8: 275-80. PMID: 18650159, DOI: 10.3816/CBC.2008.n.032.
  • Lymphopenia associated with adjuvant anthracycline/ taxane regimens.Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clinical Breast Cancer 2008, 8: 352-6. PMID: 18757263, DOI: 10.3816/CBC.2008.n.041.
  • The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.Winer E. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer. Clinical Advances In Hematology & Oncology : H&O 2008, 6: 573-4. PMID: 18820598.
  • Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ.Ligibel JA, Partridge A, Giobbie-Hurder A, Golshan M, Emmons K, Winer EP. Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ. Annals Of Surgical Oncology 2009, 16: 106-12. PMID: 18953612, PMCID: PMC5842912, DOI: 10.1245/s10434-008-0174-x.
  • Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 5994-6000. PMID: 19029413, DOI: 10.1200/JCO.2008.18.1420.
  • Reducing disparities in breast cancer care: a daunting but essential responsibility.Freedman RA, Winer EP. Reducing disparities in breast cancer care: a daunting but essential responsibility. Journal Of The National Cancer Institute 2008, 100: 1661-3. PMID: 19033563, DOI: 10.1093/jnci/djn412.
  • VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2008, 14: 7871-7. PMID: 19047116, DOI: 10.1158/1078-0432.CCR-08-0593.
  • Triple-negative breast cancer: risk factors to potential targets.Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2008, 14: 8010-8. PMID: 19088017, DOI: 10.1158/1078-0432.CCR-08-1208.
  • Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 812-26. PMID: 19103723, PMCID: PMC2645086, DOI: 10.1200/JCO.2008.21.2134.
  • Trends in racial and age disparities in definitive local therapy of early-stage breast cancer.Freedman RA, He Y, Winer EP, Keating NL. Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 713-9. PMID: 19103731, DOI: 10.1200/JCO.2008.17.9234.
  • Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast.Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Archives Of Pathology & Laboratory Medicine 2009, 133: 15-25. PMID: 19123730, DOI: 10.5858/133.1.15.
  • Sharing study results with trial participants: time for action.Partridge AH, Winer EP. Sharing study results with trial participants: time for action. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 838-9. PMID: 19164202, DOI: 10.1200/JCO.2008.20.0865.
  • Breast cancer. Clinical practice guidelines in oncology.Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2009, 7: 122-92. PMID: 19200416, DOI: 10.6004/jnccn.2009.0012.
  • Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Research And Treatment 2009, 117: 615-23. PMID: 19294501, PMCID: PMC4578795, DOI: 10.1007/s10549-009-0366-5.
  • A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clinical Breast Cancer 2009, 9: 39-44. PMID: 19299239, DOI: 10.3816/CBC.2009.n.007.
  • Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clinical Breast Cancer 2009, 9: 101-7. PMID: 19433391, DOI: 10.3816/CBC.2009.n.019.
  • Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors.Ligibel JA, Giobbie-Hurder A, Olenczuk D, Campbell N, Salinardi T, Winer EP, Mantzoros CS. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes & Control : CCC 2009, 20: 1523-8. PMID: 19434504, DOI: 10.1007/s10552-009-9358-3.
  • Adjuvant chemotherapy in older women with early-stage breast cancer.Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. The New England Journal Of Medicine 2009, 360: 2055-65. PMID: 19439741, PMCID: PMC3082436, DOI: 10.1056/NEJMoa0810266.
  • Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery?Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Medical Care 2009, 47: 765-73. PMID: 19536008, DOI: 10.1097/MLR.0b013e31819e1fe7.
  • International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. Journal Of The National Cancer Institute 2009, 101: 1174-81. PMID: 19657108, PMCID: PMC2736293, DOI: 10.1093/jnci/djp235.
  • The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.Ligibel JA, Winer EP. The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. Journal Of The National Comprehensive Cancer Network : JNCCN 2003, 1: 215-21. PMID: 19768880, DOI: 10.6004/jnccn.2003.0020.
  • Protocol for the examination of specimens from patients with invasive carcinoma of the breast.Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Archives Of Pathology & Laboratory Medicine 2009, 133: 1515-38. PMID: 19792042, DOI: 10.5858/133.10.1515.
  • Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer.Ligibel JA, Winer EP. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer. Women's Health (London, England) 2006, 2: 89-97. PMID: 19803930, DOI: 10.2217/17455057.2.1.89.
  • Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 5671-3. PMID: 19884535, DOI: 10.1200/JCO.2009.24.2222.
  • Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 6117-23. PMID: 19901120, PMCID: PMC3664032, DOI: 10.1200/JCO.2008.20.2952.
  • Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D, Ganz PA, Kramer B. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 6052-69. PMID: 19901123, DOI: 10.1200/JCO.2009.26.6171.
  • On mammography--more agreement than disagreement.Partridge AH, Winer EP. On mammography--more agreement than disagreement. The New England Journal Of Medicine 2009, 361: 2499-501. PMID: 19940286, DOI: 10.1056/NEJMp0911288.
  • Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women.Kouri EM, He Y, Winer EP, Keating NL. Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Research And Treatment 2010, 121: 743-51. PMID: 19949856, DOI: 10.1007/s10549-009-0643-3.
  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet. Oncology 2010, 11: 55-65. PMID: 20005174, PMCID: PMC3058239, DOI: 10.1016/S1470-2045(09)70314-6.
  • Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer.Freedman RA, Winer EP. Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. Breast (Edinburgh, Scotland) 2010, 19: 69-75. PMID: 20034796, DOI: 10.1016/j.breast.2009.11.009.
  • Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2010, 28: 1145-53. PMID: 20100965, PMCID: PMC2834466, DOI: 10.1200/JCO.2009.22.4725.
  • The role of socioeconomic status in adjustment after ductal carcinoma in situ.de Moor JS, Partridge AH, Winer EP, Ligibel J, Emmons KM. The role of socioeconomic status in adjustment after ductal carcinoma in situ. Cancer 2010, 116: 1218-25. PMID: 20143325, PMCID: PMC3072709, DOI: 10.1002/cncr.24832.
  • International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? Journal Of The National Cancer Institute 2010, 102: 456-63. PMID: 20220104, PMCID: PMC3298957, DOI: 10.1093/jnci/djq029.
  • Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2010, 28: 2418-22. PMID: 20368559, PMCID: PMC2881723, DOI: 10.1200/JCO.2009.26.4671.
  • Outcomes following local therapy for early-stage breast cancer in non-trial populations.Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, Volya R. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Research And Treatment 2011, 125: 803-13. PMID: 20376555, PMCID: PMC2924956, DOI: 10.1007/s10549-010-0865-4.
  • Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2010, 28: 2982-8. PMID: 20479410, PMCID: PMC3664034, DOI: 10.1200/JCO.2009.26.5900.
  • Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.Mandelblatt JS, Sheppard VB, Hurria A, Kimmick G, Isaacs C, Taylor KL, Kornblith AB, Noone AM, Luta G, Tallarico M, Barry WT, Hunegs L, Zon R, Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H. Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2010, 28: 3146-53. PMID: 20516438, PMCID: PMC2903313, DOI: 10.1200/JCO.2009.24.3295.
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett ED, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. Journal Of The National Cancer Institute 2010, 102: 942-9. PMID: 20554945, PMCID: PMC2897879, DOI: 10.1093/jnci/djq211.
  • Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial.Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause (New York, N.Y.) 2010, 17: 908-16. PMID: 20581724, DOI: 10.1097/gme.0b013e3181dbee1b.
  • American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2010, 28: 3784-96. PMID: 20625130, PMCID: PMC5569672, DOI: 10.1200/JCO.2009.26.3756.
  • Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer.Ligibel JA, Partridge A, Giobbie-Hurder A, Campbell N, Shockro L, Salinardi T, Winer EP. Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer. Journal Of Women's Health (2002) 2010, 19: 1553-9. PMID: 20629579, DOI: 10.1089/jwh.2009.1760.
  • Cardiac toxicity from systemic cancer therapy: a comprehensive review.Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Progress In Cardiovascular Diseases 2010, 53: 94-104. PMID: 20728696, DOI: 10.1016/j.pcad.2010.05.006.
  • Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2010, 16: 4702-10. PMID: 20858840, PMCID: PMC2948607, DOI: 10.1158/1078-0432.CCR-10-0939.
  • Triple-negative breast cancer: disease entity or title of convenience?Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews. Clinical Oncology 2010, 7: 683-92. PMID: 20877296, DOI: 10.1038/nrclinonc.2010.154.
  • Does neoadjuvant bevacizumab increase surgical complications in breast surgery?Golshan M, Garber JE, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Annals Of Surgical Oncology 2011, 18: 733-7. PMID: 20882415, DOI: 10.1245/s10434-010-1366-8.
  • The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care.Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 2011, 117: 180-9. PMID: 20939011, DOI: 10.1002/cncr.25542.
  • Breast cancer: noninvasive and special situations.Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: noninvasive and special situations. Journal Of The National Comprehensive Cancer Network : JNCCN 2010, 8: 1182-207. PMID: 20971842, DOI: 10.6004/jnccn.2010.0087.
  • Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight.Lin NU, Winer EP. Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29: 251-3. PMID: 21149664, DOI: 10.1200/JCO.2010.32.5290.
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.Kornblith AB, Lan L, Archer L, Partridge A, Kimmick G, Hudis C, Winer E, Casey R, Bennett S, Cohen HJ, Muss HB. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29: 1022-8. PMID: 21300923, PMCID: PMC3068052, DOI: 10.1200/JCO.2010.29.9859.
  • Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2011, 17: 3490-9. PMID: 21372222, DOI: 10.1158/1078-0432.CCR-10-1359.
  • Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference.Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Annals Of Surgical Oncology 2011, 18: 2885-92. PMID: 21431404, DOI: 10.1245/s10434-011-1666-7.
  • p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2011, 17: 5170-8. PMID: 21693655, PMCID: PMC3149770, DOI: 10.1158/1078-0432.CCR-11-0484.
  • Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. Journal Of Neuro-oncology 2011, 105: 613-20. PMID: 21706359, DOI: 10.1007/s11060-011-0629-y.
  • CMF revisited in the 21st century.Munzone E, Curigliano G, Burstein HJ, Winer EP, Goldhirsch A. CMF revisited in the 21st century. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2012, 23: 305-11. PMID: 21715566, DOI: 10.1093/annonc/mdr309.
  • American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities.Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA. American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29: 3816-24. PMID: 21810680, DOI: 10.1200/JCO.2011.35.8903.
  • Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.Ligibel JA, James O'Malley A, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Research And Treatment 2012, 131: 589-97. PMID: 21881937, DOI: 10.1007/s10549-011-1754-1.
  • Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. The Oncologist 2011, 16: 1359-66. PMID: 21934103, PMCID: PMC3228065, DOI: 10.1634/theoncologist.2011-0048.
  • Adjuvant chemotherapy in luminal breast cancers.Lim E, Winer EP. Adjuvant chemotherapy in luminal breast cancers. Breast (Edinburgh, Scotland) 2011, 20 Suppl 3: S128-31. PMID: 22015279, DOI: 10.1016/S0960-9776(11)70309-5.
  • Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates?Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? The Breast Journal 2012, 18: 23-7. PMID: 22017599, DOI: 10.1111/j.1524-4741.2011.01178.x.
  • Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Research And Treatment 2012, 131: 1061-6. PMID: 22080245, DOI: 10.1007/s10549-011-1872-9.
  • Breast cancer survivors' perceptions of survivorship care options.Mayer EL, Gropper AB, Neville BA, Partridge AH, Cameron DB, Winer EP, Earle CC. Breast cancer survivors' perceptions of survivorship care options. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 158-63. PMID: 22162585, PMCID: PMC4874208, DOI: 10.1200/JCO.2011.36.9264.
  • The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research.Meropol NJ, Kris MG, Winer EP. The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 690-1. PMID: 22215747, DOI: 10.1200/JCO.2011.40.1125.
  • Should a sentinel node biopsy be performed in patients with high-risk breast cancer?Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS. Should a sentinel node biopsy be performed in patients with high-risk breast cancer? International Journal Of Breast Cancer 2011, 2011: 973245. PMID: 22295240, PMCID: PMC3262582, DOI: 10.4061/2011/973245.
  • A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research And Treatment 2012, 133: 1057-65. PMID: 22418700, PMCID: PMC3387495, DOI: 10.1007/s10549-012-2003-y.
  • Quality of life in long-term survivors of metastatic breast cancer.Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH. Quality of life in long-term survivors of metastatic breast cancer. Clinical Breast Cancer 2012, 12: 119-26. PMID: 22444718, DOI: 10.1016/j.clbc.2012.01.010.
  • Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012, 118: 5463-72. PMID: 22544643, PMCID: PMC3611659, DOI: 10.1002/cncr.27581.
  • The effect of age on delay in diagnosis and stage of breast cancer.Partridge AH, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. The effect of age on delay in diagnosis and stage of breast cancer. The Oncologist 2012, 17: 775-82. PMID: 22554997, PMCID: PMC3380876, DOI: 10.1634/theoncologist.2011-0469.
  • Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 2179-82. PMID: 22614986, PMCID: PMC6076002, DOI: 10.1200/JCO.2012.42.0695.
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 2615-23. PMID: 22665533, PMCID: PMC3413275, DOI: 10.1200/JCO.2010.34.5579.
  • Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).Ruddy KJ, Pitcher BN, Archer LE, Cohen HJ, Winer EP, Hudis CA, Muss HB, Partridge AH. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2012, 23: 3075-3081. PMID: 22767584, PMCID: PMC3501229, DOI: 10.1093/annonc/mds133.
  • Patterns of bone density evaluation in a community population treated with aromatase inhibitors.Ligibel JA, O'Malley AJ, Fisher M, Daniel GW, Winer EP, Keating NL. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Research And Treatment 2012, 134: 1305-13. PMID: 22791365, PMCID: PMC3449001, DOI: 10.1007/s10549-012-2151-0.
  • Aromatase inhibition in obese women: how much is enough?Ligibel JA, Winer EP. Aromatase inhibition in obese women: how much is enough? Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 2940-2. PMID: 22802318, DOI: 10.1200/JCO.2012.43.7244.
  • Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ.Bober SL, Giobbie-Hurder A, Emmons KM, Winer E, Partridge A. Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. The Journal Of Sexual Medicine 2013, 10: 370-7. PMID: 22812628, DOI: 10.1111/j.1743-6109.2012.02852.x.
  • Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 4071-6. PMID: 22826271, PMCID: PMC3494835, DOI: 10.1200/JCO.2011.40.6405.
  • Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis.Keating NL, Kouri EM, He Y, West DW, Winer EP. Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis. Cancer 2013, 119: 250-8. PMID: 22833148, DOI: 10.1002/cncr.27757.
  • A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2012, 18: 5099-109. PMID: 22843789, PMCID: PMC3445665, DOI: 10.1158/1078-0432.CCR-12-1590.
  • Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?Hudis CA, Citron ML, Muss H, Norton L, Winer EP. Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 3148-9; author reply 3149-50. PMID: 22851555, DOI: 10.1200/JCO.2012.43.4746.
  • Survival implications associated with variation in mastectomy rates for early-staged breast cancer.Brooks JM, Chrischilles EA, Landrum MB, Wright KB, Fang G, Winer EP, Keating NL. Survival implications associated with variation in mastectomy rates for early-staged breast cancer. International Journal Of Surgical Oncology 2012, 2012: 127854. PMID: 22928097, PMCID: PMC3423912, DOI: 10.1155/2012/127854.
  • The natural history of hormone receptor-positive breast cancer.Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park, N.Y.) 2012, 26: 688-94, 696. PMID: 22957400.
  • Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Research And Treatment 2012, 136: 169-78. PMID: 23001754, PMCID: PMC5472381, DOI: 10.1007/s10549-012-2256-5.
  • Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 283-291. PMID: 23022997, PMCID: PMC3551479, DOI: 10.1093/annonc/mds286.
  • Time to diagnosis and breast cancer stage by race/ethnicity.Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Research And Treatment 2012, 136: 813-21. PMID: 23099438, PMCID: PMC3513497, DOI: 10.1007/s10549-012-2304-1.
  • Body image in recently diagnosed young women with early breast cancer.Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Kereakoglow S, Borges VF, Come SE, Schapira L, Winer EP, Partridge AH. Body image in recently diagnosed young women with early breast cancer. Psycho-oncology 2013, 22: 1849-55. PMID: 23132765, PMCID: PMC3594059, DOI: 10.1002/pon.3221.
  • Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Research And Treatment 2012, 136: 919-26. PMID: 23143284, DOI: 10.1007/s10549-012-2333-9.
  • Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 491-9. PMID: 23204130, PMCID: PMC3549006, DOI: 10.1158/1078-0432.CCR-12-2618.
  • Model program to improve care for a unique cancer population: young women with breast cancer.Partridge AH, Ruddy KJ, Kennedy J, Winer EP. Model program to improve care for a unique cancer population: young women with breast cancer. Journal Of Oncology Practice / American Society Of Clinical Oncology 2012, 8: e105-10. PMID: 23277772, PMCID: PMC3439235, DOI: 10.1200/JOP.2011.000501.
  • Quality of life and symptoms in male breast cancer survivors.Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow S, Winer EP, Partridge AH. Quality of life and symptoms in male breast cancer survivors. Breast (Edinburgh, Scotland) 2013, 22: 197-199. PMID: 23313328, DOI: 10.1016/j.breast.2012.12.014.
  • High performance teamwork training and systems redesign in outpatient oncology.Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S. High performance teamwork training and systems redesign in outpatient oncology. BMJ Quality & Safety 2013, 22: 405-13. PMID: 23349386, DOI: 10.1136/bmjqs-2012-000948.
  • Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast (Edinburgh, Scotland) 2013, 22: 525-31. PMID: 23352568, PMCID: PMC3713786, DOI: 10.1016/j.breast.2012.12.006.
  • Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 1434-43. PMID: 23425944, DOI: 10.1093/annonc/mdt025.
  • Attitudes of patients with metastatic breast cancer toward research biopsies.Seah DS, Scott SM, Najita J, Openshaw T, Krag K, Frank E, Sohl J, Stadler ZK, Garrett M, Silverman SG, Peppercorn J, Winer EP, Come SE, Lin NU. Attitudes of patients with metastatic breast cancer toward research biopsies. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 1853-1859. PMID: 23493137, DOI: 10.1093/annonc/mdt067.
  • Long-term risk perceptions of women with ductal carcinoma in situ.Ruddy KJ, Meyer ME, Giobbie-Hurder A, Emmons KM, Weeks JC, Winer EP, Partridge AH. Long-term risk perceptions of women with ductal carcinoma in situ. The Oncologist 2013, 18: 362-8. PMID: 23568001, PMCID: PMC3639521, DOI: 10.1634/theoncologist.2012-0376.
  • International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast (Edinburgh, Scotland) 2013, 22: 203-10. PMID: 23601761, DOI: 10.1016/j.breast.2013.03.006.
  • Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care?Freedman RA, He Y, Winer EP, Keating NL. Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Services Research 2013, 48: 1669-83. PMID: 23663229, PMCID: PMC3796107, DOI: 10.1111/1475-6773.12063.
  • Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907.Freedman RA, Pitcher B, Keating NL, Ballman KV, Mandelblatt J, Kornblith AB, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Research And Treatment 2013, 139: 607-16. PMID: 23681403, PMCID: PMC3920483, DOI: 10.1007/s10549-013-2562-6.
  • Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2013, 31: 2382-7. PMID: 23690420, PMCID: PMC3691356, DOI: 10.1200/JCO.2012.45.2615.
  • Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2013, 31: 2692-8. PMID: 23752109, DOI: 10.1200/JCO.2012.44.1956.
  • A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. European Journal Of Cancer (Oxford, England : 1990) 2013, 49: 2972-8. PMID: 23810467, PMCID: PMC3956307, DOI: 10.1016/j.ejca.2013.05.020.
  • A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Research And Treatment 2013, 140: 331-9. PMID: 23868188, DOI: 10.1007/s10549-013-2632-9.
  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 2206-23. PMID: 23917950, PMCID: PMC3755334, DOI: 10.1093/annonc/mdt303.
  • Q&A: Eric Winer on neoadjuvant clinical trials.Winer E. Q&A: Eric Winer on neoadjuvant clinical trials. Cancer Discovery 2013, 3: 832. PMID: 23928759, DOI: 10.1158/2159-8290.CD-ND2013-017.
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer 2013, 119: 3943-51. PMID: 24037735, DOI: 10.1002/cncr.28284.
  • Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Annals Of Internal Medicine 2013, 159: 373-81. PMID: 24042365, PMCID: PMC3968260, DOI: 10.7326/0003-4819-159-6-201309170-00003.
  • Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Research And Treatment 2013, 141: 421-7. PMID: 24062210, DOI: 10.1007/s10549-013-2700-1.
  • Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al.Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2013, 31: 4571-3. PMID: 24190113, DOI: 10.1200/JCO.2013.52.9438.
  • A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Research And Treatment 2013, 142: 405-14. PMID: 24197661, DOI: 10.1007/s10549-013-2754-0.
  • Breast cancer presentation and diagnostic delays in young women.Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH. Breast cancer presentation and diagnostic delays in young women. Cancer 2014, 120: 20-5. PMID: 24347383, DOI: 10.1002/cncr.28287.
  • A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future.Sledge GW, Cardoso F, Winer EP, Piccart MJ. A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. American Society Of Clinical Oncology Educational Book / ASCO. American Society Of Clinical Oncology. Meeting 2012, 28-38. PMID: 24451704, DOI: 10.14694/EdBook_AM.2012.32.306.
  • Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. Journal Of The National Comprehensive Cancer Network : JNCCN 2014, 12: 71-80. PMID: 24453294, DOI: 10.6004/jnccn.2014.0008.
  • A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901.Mandelblatt JS, Makgoeng SB, Luta G, Hurria A, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher B, Winer EP, Hudis C, Cohen HJ, Muss HB. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. Journal Of Geriatric Oncology 2013, 4: 353-61. PMID: 24472479, PMCID: PMC3910230, DOI: 10.1016/j.jgo.2013.05.004.
  • Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). The Pharmacogenomics Journal 2014, 14: 336-42. PMID: 24513692, PMCID: PMC4111770, DOI: 10.1038/tpj.2014.2.
  • Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 927-34. PMID: 24516021, PMCID: PMC3948095, DOI: 10.1200/JCO.2013.51.1261.
  • Defining success in neoadjuvant breast cancer trials.Carey LA, Winer EP. Defining success in neoadjuvant breast cancer trials. Lancet 2014, 384: 115-6. PMID: 24529559, DOI: 10.1016/S0140-6736(14)60034-9.
  • Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 1202-9. PMID: 24663045, PMCID: PMC3986383, DOI: 10.1200/JCO.2013.54.0518.
  • Male breast cancer networking and telephone support group: a model for supporting a unique population.Farrell E, Borstelmann N, Meyer F, Partridge A, Winer E, Ruddy K. Male breast cancer networking and telephone support group: a model for supporting a unique population. Psycho-oncology 2014, 23: 956-8. PMID: 24700635, DOI: 10.1002/pon.3519.
  • Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy.Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Research And Treatment 2014, 145: 491-501. PMID: 24756187, DOI: 10.1007/s10549-014-2968-9.
  • Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 2255-69. PMID: 24868023, PMCID: PMC4876310, DOI: 10.1200/JCO.2013.54.2258.
  • Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. The New England Journal Of Medicine 2014, 371: 107-18. PMID: 24881463, PMCID: PMC4175521, DOI: 10.1056/NEJMoa1404037.
  • Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 2142-50. PMID: 24888816, PMCID: PMC4076026, DOI: 10.1200/JCO.2013.53.1608.
  • Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 3483-9. PMID: 24888818, PMCID: PMC4209100, DOI: 10.1200/JCO.2014.56.2561.
  • Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901.Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. Journal Of Cancer Survivorship : Research And Practice 2014, 8: 627-37. PMID: 24917307, PMCID: PMC4386650, DOI: 10.1007/s11764-014-0371-5.
  • Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 2318-27. PMID: 24934786, PMCID: PMC4105485, DOI: 10.1200/JCO.2013.51.7367.
  • Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 2311-7. PMID: 24934787, PMCID: PMC4105484, DOI: 10.1200/JCO.2013.53.7142.
  • Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.Ruddy KJ, DeSantis SD, Barry W, Guo H, Block CC, Borges V, Winer EP, Partridge AH. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clinical Breast Cancer 2014, 14: 413-6. PMID: 24970714, DOI: 10.1016/j.clbc.2014.04.007.
  • TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, Prat A, Perou CM, Wolff AC, Carey LA. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Research And Treatment 2014, 146: 557-66. PMID: 25001612, PMCID: PMC4112043, DOI: 10.1007/s10549-014-3039-y.
  • Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).Klepin HD, Pitcher BN, Ballman KV, Kornblith AB, Hurria A, Winer EP, Hudis C, Cohen HJ, Muss HB, Kimmick GG. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). Journal Of Oncology Practice / American Society Of Clinical Oncology 2014, 10: e285-92. PMID: 25074878, PMCID: PMC4161730, DOI: 10.1200/JOP.2014.001388.
  • Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 13-21. PMID: 25092775, PMCID: PMC4268249, DOI: 10.1200/JCO.2014.57.0572.
  • Predicting response and survival in chemotherapy-treated triple-negative breast cancer.Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal Of Cancer 2014, 111: 1532-41. PMID: 25101563, PMCID: PMC4200088, DOI: 10.1038/bjc.2014.444.
  • Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clinical Breast Cancer 2015, 15: 24-30. PMID: 25205424, DOI: 10.1016/j.clbc.2014.07.010.
  • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet. Oncology 2014, 15: 1207-14. PMID: 25218906, PMCID: PMC4294183, DOI: 10.1016/S1470-2045(14)70391-2.
  • Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 3744-52. PMID: 25332249, PMCID: PMC4226805, DOI: 10.1200/JCO.2014.55.5730.
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 3959-66. PMID: 25348000, PMCID: PMC4251959, DOI: 10.1200/JCO.2014.56.7941.
  • Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 3840-7. PMID: 25349301, DOI: 10.1200/JCO.2014.55.2984.
  • Adjuvant ovarian suppression in premenopausal breast cancer.Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant ovarian suppression in premenopausal breast cancer. The New England Journal Of Medicine 2015, 372: 436-46. PMID: 25495490, PMCID: PMC4341825, DOI: 10.1056/NEJMoa1412379.
  • Reply to V. Amoroso et al.Shulman LN, Berry DA, Cirrincione CT, Hudis CA, Winer EP. Reply to V. Amoroso et al. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 291. PMID: 25512457, DOI: 10.1200/JCO.2014.59.1875.
  • Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.Tung NM, Winer EP. Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 969-71. PMID: 25559817, DOI: 10.1200/JCO.2014.59.6031.
  • Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 701-8. PMID: 25605861, PMCID: PMC4334774, DOI: 10.1200/JCO.2014.57.6298.
  • Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer 2015, 121: 1937-48. PMID: 25757412, PMCID: PMC4457605, DOI: 10.1002/cncr.29310.
  • TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 1902-9. PMID: 25847936, PMCID: PMC4451173, DOI: 10.1200/JCO.2014.57.6660.
  • Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast.Sagara Y, Barry WT, Mallory MA, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Annals Of Surgical Oncology 2015, 22: 4280-6. PMID: 25893416, PMCID: PMC4801503, DOI: 10.1245/s10434-015-4570-8.
  • Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.Rosenberg SM, Sepucha K, Ruddy KJ, Tamimi RM, Gelber S, Meyer ME, Schapira L, Come SE, Borges VF, Golshan M, Winer EP, Partridge AH. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Annals Of Surgical Oncology 2015, 22: 3809-15. PMID: 25930247, PMCID: PMC4598267, DOI: 10.1245/s10434-015-4572-6.
  • Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2015, 26: 1533-46. PMID: 25939896, PMCID: PMC4511219, DOI: 10.1093/annonc/mdv221.
  • Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 2254-61. PMID: 25964252, PMCID: PMC4486344, DOI: 10.1200/JCO.2014.57.1349.
  • Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii H, Winer EP, Freedman RA. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Research And Treatment 2015, 151: 697-707. PMID: 26022349, DOI: 10.1007/s10549-015-3432-1.
  • Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women.Collins LC, Gelber S, Marotti JD, White S, Ruddy K, Brachtel EF, Schapira L, Come SE, Borges VF, Schedin P, Warner E, Wensley T, Tamimi RM, Winer EP, Partridge AH. Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. The Oncologist 2015, 20: 713-8. PMID: 26025931, PMCID: PMC4492229, DOI: 10.1634/theoncologist.2014-0412.
  • Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 2361-9. PMID: 26056183, PMCID: PMC4500830, DOI: 10.1200/JCO.2014.59.5298.
  • Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal Of The National Cancer Institute 2015, 107 PMID: 26113580, PMCID: PMC4651106, DOI: 10.1093/jnci/djv179.
  • Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2.Clark S, Bluman LG, Borstelmann N, Regan K, Winer EP, Rimer BK, Skinner CS. Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2. Journal Of Genetic Counseling 2000, 9: 219-35. PMID: 26141318, DOI: 10.1023/A:1009463905057.
  • Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 2772-9. PMID: 26215945, PMCID: PMC4550691, DOI: 10.1200/JCO.2015.60.8133.
  • Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, Hudis C, Winer E, Ollila DW. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals Of Surgery 2015, 262: 434-9; discussion 438-9. PMID: 26222764, PMCID: PMC4710511, DOI: 10.1097/SLA.0000000000001417.
  • Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.Seah DS, Scott S, Guo H, Najita J, Lederman R, Frank E, Sohl J, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin NU. Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. The Oncologist 2015, 20: 992-1000. PMID: 26240134, PMCID: PMC4571800, DOI: 10.1634/theoncologist.2015-0112.
  • Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Stover DG, Winer EP. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. Breast (Edinburgh, Scotland) 2015, 24 Suppl 2: S132-5. PMID: 26255198, DOI: 10.1016/j.breast.2015.07.032.
  • Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery 2015, 5: 1164-1177. PMID: 26410082, PMCID: PMC4916970, DOI: 10.1158/2159-8290.CD-15-0369.
  • Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM, Winer EP, Hammond SP, Baden LR. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Research And Treatment 2015, 154: 359-67. PMID: 26420402, DOI: 10.1007/s10549-015-3573-2.
  • POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.Goel S, Winer EP. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. Oncology (Williston Park, N.Y.) 2015, 29: 797-8, 802. PMID: 26573058.
  • Timeliness in Breast Cancer Treatment-The Sooner, the Better.Waks AG, King TA, Winer EP. Timeliness in Breast Cancer Treatment-The Sooner, the Better. JAMA Oncology 2016, 2: 302-4. PMID: 26658500, DOI: 10.1001/jamaoncol.2015.4506.
  • Response.Ligibel JA, Winer E, Hudis CA, Barry WT. Response. Journal Of The National Cancer Institute 2016, 108 PMID: 26719886, DOI: 10.1093/jnci/djv334.
  • Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers.Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Research And Treatment 2016, 155: 569-78. PMID: 26868124, DOI: 10.1007/s10549-016-3707-1.
  • Randomized trial of a physical activity intervention in women with metastatic breast cancer.Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, Lin NU, Winer EP. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer 2016, 122: 1169-77. PMID: 26872302, DOI: 10.1002/cncr.29899.
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 1689-701. PMID: 26884586, DOI: 10.1200/JCO.2015.65.9573.
  • Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 3764-73. PMID: 26957554, PMCID: PMC6773427, DOI: 10.1158/1078-0432.CCR-15-2477.
  • Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 1460-8. PMID: 26976419, PMCID: PMC4872307, DOI: 10.1200/JCO.2015.65.0747.
  • A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 26-34. PMID: 27126994, PMCID: PMC5085926, DOI: 10.1158/1078-0432.CCR-16-0134.
  • Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 2602-9. PMID: 27138575, PMCID: PMC5012690, DOI: 10.1200/JCO.2015.66.1595.
  • TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Leo AD, Malorni L. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 5755-5764. PMID: 27185372, PMCID: PMC5124409, DOI: 10.1158/1078-0432.CCR-16-0148.
  • Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. The New England Journal Of Medicine 2016, 375: 209-19. PMID: 27264120, PMCID: PMC5024713, DOI: 10.1056/NEJMoa1604700.
  • Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research And Treatment 2016, 157: 587-96. PMID: 27271765, DOI: 10.1007/s10549-016-3845-5.
  • The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 6039-6050. PMID: 27330058, PMCID: PMC5161615, DOI: 10.1158/1078-0432.CCR-16-0471.
  • I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.Carey LA, Winer EP. I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment. The New England Journal Of Medicine 2016, 375: 83-4. PMID: 27406352, DOI: 10.1056/NEJMe1603691.
  • Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 3308-14. PMID: 27480155, DOI: 10.1200/JCO.2015.65.8013.
  • Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Research And Treatment 2016, 159: 151-62. PMID: 27484879, DOI: 10.1007/s10549-016-3927-4.
  • Perils of the Pathologic Complete Response.Rose BS, Winer EP, Mamon HJ. Perils of the Pathologic Complete Response. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 3959-3962. PMID: 27551115, DOI: 10.1200/JCO.2016.68.1718.
  • Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Research And Treatment 2016, 160: 297-304. PMID: 27704226, PMCID: PMC5189982, DOI: 10.1007/s10549-016-4006-6.
  • Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, O'Keeffe B, Shapiro GI, Winer EP. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Research And Treatment 2016, 160: 305-312. PMID: 27714541, PMCID: PMC5065609, DOI: 10.1007/s10549-016-4001-y.
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. The New England Journal Of Medicine 2016, 375: 1738-1748. PMID: 27717303, DOI: 10.1056/NEJMoa1609709.
  • Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast (Edinburgh, Scotland) 2016, 30: 136-140. PMID: 27721193, DOI: 10.1016/j.breast.2016.09.013.
  • Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. The Oncologist 2017, 22: 25-32. PMID: 27789775, PMCID: PMC5313267, DOI: 10.1634/theoncologist.2016-0229.
  • Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Research And Treatment 2017, 161: 363-373. PMID: 27866278, PMCID: PMC5226883, DOI: 10.1007/s10549-016-4051-1.
  • Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review.Freedman RA, Keating NL, Partridge AH, Muss HB, Hurria A, Winer EP. Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. JAMA Oncology 2017, 3: 402-409. PMID: 27892991, PMCID: PMC5540165, DOI: 10.1001/jamaoncol.2016.3931.
  • Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A. Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 421-431. PMID: 27992272, PMCID: PMC5455700, DOI: 10.1200/JCO.2016.69.4182.
  • 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 3053-3060. PMID: 28011460, PMCID: PMC5474190, DOI: 10.1158/1078-0432.CCR-16-2197.
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 1061-1069. PMID: 28045625, PMCID: PMC5455353, DOI: 10.1200/JCO.2016.69.4406.
  • Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Journal Of The American College Of Surgeons 2017, 224: 688-694. PMID: 28089784, PMCID: PMC5616181, DOI: 10.1016/j.jamcollsurg.2016.12.036.
  • Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study.Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. The Oncologist 2017, 22: 386-393. PMID: 28242790, PMCID: PMC5388378, DOI: 10.1634/theoncologist.2016-0369.
  • Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network : JNCCN 2017, 15: 316-324. PMID: 28275032, DOI: 10.6004/jnccn.2017.0031.
  • Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, Barginear M, Freedman RA, Artz A, Klepin HD, Lafky JM, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A, Mandelblatt J. Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Research And Treatment 2017, 163: 391-398. PMID: 28283904, PMCID: PMC5508575, DOI: 10.1007/s10549-017-4188-6.
  • Survival benefit needed to undergo chemotherapy: Patient and physician preferences.Vaz-Luis I, O'Neill A, Sepucha K, Miller KD, Baker E, Dang CT, Northfelt DW, Winer EP, Sledge GW, Schneider B, Partridge AH. Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 2017, 123: 2821-2828. PMID: 28323331, PMCID: PMC5517352, DOI: 10.1002/cncr.30671.
  • Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).Mandelblatt JS, Cai L, Luta G, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Research And Treatment 2017, 164: 107-117. PMID: 28364214, PMCID: PMC5479131, DOI: 10.1007/s10549-017-4222-8.
  • Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?Garrido-Castro AC, Winer EP. Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy? Journal Of The National Cancer Institute 2017, 109 PMID: 28376163, DOI: 10.1093/jnci/djw316.
  • Reply to S. Sorscher.Rose BS, Winer EP, Mamon HJ. Reply to S. Sorscher. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 1746-1747. PMID: 28524778, DOI: 10.1200/JCO.2017.72.2876.
  • Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). The AAPS Journal 2017, 19: 1411-1423. PMID: 28620884, PMCID: PMC5711539, DOI: 10.1208/s12248-017-0101-9.
  • Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 5687-5695. PMID: 28679771, PMCID: PMC6746403, DOI: 10.1158/1078-0432.CCR-17-0900.
  • PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer 2016, 2 PMID: 28691057, PMCID: PMC5501351, DOI: 10.1038/npjbcancer.2015.23.
  • Breast cancer: T-DM1 - an important agent in the history of breast cancer management.Metzger-Filho O, Winer EP. Breast cancer: T-DM1 - an important agent in the history of breast cancer management. Nature Reviews. Clinical Oncology 2017, 14: 651-652. PMID: 28786416, DOI: 10.1038/nrclinonc.2017.123.
  • Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302).Hopkins JO, Allred J, Hurria A, Jatoi A, Lafky JM, Cohen H, Hudis C, Winer E, Mandelblatt J, Partridge A, Carey L, Muss HB. Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). Breast Cancer Research And Treatment 2017, 166: 793-808. PMID: 28825227, PMCID: PMC5771504, DOI: 10.1007/s10549-017-4454-7.
  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28: 1700-1712. PMID: 28838210, PMCID: PMC6246241, DOI: 10.1093/annonc/mdx308.
  • Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2018, 29: 281-282. PMID: 29045519, PMCID: PMC6246427, DOI: 10.1093/annonc/mdx543.
  • Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications 2017, 8: 1324. PMID: 29109393, PMCID: PMC5673918, DOI: 10.1038/s41467-017-00965-y.
  • Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.Poorvu PD, Winer EP. Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway. Journal Of The National Cancer Institute 2018, 110: 443-445. PMID: 29237035, DOI: 10.1093/jnci/djx264.
  • Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, Hassett MJ. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Research And Treatment 2018, 168: 727-737. PMID: 29332137, DOI: 10.1007/s10549-018-4659-4.
  • Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 884-890. PMID: 29373071, PMCID: PMC5858523, DOI: 10.1200/JCO.2016.71.3495.
  • Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?Kabraji S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 1795-1804. PMID: 29437794, PMCID: PMC5899637, DOI: 10.1158/1078-0432.CCR-17-3351.
  • Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, Kwiatkowski N, Zhang T, Gray N, Melchers D, Houtman R, Liu XS, Cohen O, Wagle N, Winer EP, Zhao J, Brown M. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell 2018, 33: 173-186.e5. PMID: 29438694, PMCID: PMC5813700, DOI: 10.1016/j.ccell.2018.01.004.
  • Breast cancer-specific survival by age: Worse outcomes for the oldest patients.Freedman RA, Keating NL, Lin NU, Winer EP, Vaz-Luis I, Lii J, Exman P, Barry WT. Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer 2018, 124: 2184-2191. PMID: 29499074, PMCID: PMC5935594, DOI: 10.1002/cncr.31308.
  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2018, 29: 1541-1547. PMID: 29718092, DOI: 10.1093/annonc/mdy155.
  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2018, 29: 2153. PMID: 29733336, PMCID: PMC6887963, DOI: 10.1093/annonc/mdx806.
  • Predicting breast cancer therapeutic response.Garrido-Castro AC, Winer EP. Predicting breast cancer therapeutic response. Nature Medicine 2018, 24: 535-537. PMID: 29736021, DOI: 10.1038/s41591-018-0033-7.
  • Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.Telli ML, Stover DG, Loi S, Aparicio S, Carey LA, Domchek SM, Newman L, Sledge GW, Winer EP. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Research And Treatment 2018, 171: 21-31. PMID: 29736741, DOI: 10.1007/s10549-018-4807-x.
  • Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer 2018, 4: 10. PMID: 29761158, PMCID: PMC5935675, DOI: 10.1038/s41523-018-0060-z.
  • Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research And Treatment 2018, 171: 325-334. PMID: 29789969, PMCID: PMC6076849, DOI: 10.1007/s10549-018-4828-5.
  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. The New England Journal Of Medicine 2018, 379: 122-137. PMID: 29863451, PMCID: PMC6193457, DOI: 10.1056/NEJMoa1803164.
  • CDK4/6 inhibition in breast cancer: current practice and future directions.Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances In Medical Oncology 2018, 10: 1758835918786451. PMID: 30038670, PMCID: PMC6050811, DOI: 10.1177/1758835918786451.
  • A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.Schöffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, Rooney I, Morrissey KM, Spoerke JM, Ng VW, Singel SM, Winer E. A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research : BCR 2018, 20: 109. PMID: 30185228, PMCID: PMC6125885, DOI: 10.1186/s13058-018-1015-x.
  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England Journal Of Medicine 2018, 379: 2108-2121. PMID: 30345906, DOI: 10.1056/NEJMoa1809615.
  • Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study.Kok M, Winer EP, Loi S. Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 13-16. PMID: 30351400, DOI: 10.1093/annonc/mdy473.
  • Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.Kensler KH, Poole EM, Heng YJ, Collins LC, Glass B, Beck AH, Hazra A, Rosner BA, Eliassen AH, Hankinson SE, Winer EP, Brown M, Tamimi RM. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. Journal Of The National Cancer Institute 2019, 111: 700-708. PMID: 30445651, PMCID: PMC6624168, DOI: 10.1093/jnci/djy173.
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 423-438. PMID: 30452337, DOI: 10.1200/JCO.18.01160.
  • Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 405-411. PMID: 30475947, DOI: 10.1093/annonc/mdy518.
  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 397-404. PMID: 30475950, DOI: 10.1093/annonc/mdy517.
  • Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.Metzger-Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz-Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist 2019, 24: e441-e449. PMID: 30518616, PMCID: PMC6656459, DOI: 10.1634/theoncologist.2018-0363.
  • Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature Genetics 2019, 51: 207-216. PMID: 30531871, DOI: 10.1038/s41588-018-0287-5.
  • Breast Cancer Treatment.Waks AG, Winer EP. Breast Cancer Treatment. JAMA 2019, 321: 316. PMID: 30667503, DOI: 10.1001/jama.2018.20751.
  • Breast Cancer Treatment: A Review.Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA 2019, 321: 288-300. PMID: 30667505, DOI: 10.1001/jama.2018.19323.
  • A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 2975-2987. PMID: 30723140, PMCID: PMC6522303, DOI: 10.1158/1078-0432.CCR-18-3160.
  • Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 1435. PMID: 30770494, DOI: 10.1158/1078-0432.CCR-18-4266.
  • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. The Lancet. Oncology 2019, 20: 570-580. PMID: 30880072, PMCID: PMC7025391, DOI: 10.1016/S1470-2045(18)30905-7.
  • Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clinical Breast Cancer 2019, 19: 399-404. PMID: 31235441, DOI: 10.1016/j.clbc.2019.05.010.
  • A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 1514-1520. PMID: 31250880, DOI: 10.1093/annonc/mdz198.
  • Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. European Journal Of Cancer (Oxford, England : 1990) 2019, 117: 91-98. PMID: 31276981, PMCID: PMC6718694, DOI: 10.1016/j.ejca.2019.06.002.
  • Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research : BCR 2019, 21: 78. PMID: 31277699, PMCID: PMC6612080, DOI: 10.1186/s13058-019-1154-8.
  • Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 2338-2348. PMID: 31339827, PMCID: PMC6900836, DOI: 10.1200/JCO.19.00647.
  • Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 1541-1557. PMID: 31373601, DOI: 10.1093/annonc/mdz235.
  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 1842. PMID: 31407010, PMCID: PMC6927326, DOI: 10.1093/annonc/mdz215.
  • Reply to A.K. Goel et al.Tolaney SM, Winer EP. Reply to A.K. Goel et al. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 2954-2955. PMID: 31518173, DOI: 10.1200/JCO.19.01822.
  • A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Research And Treatment 2020, 179: 113-123. PMID: 31541381, DOI: 10.1007/s10549-019-05445-z.
  • PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.Nixon MJ, Formisano L, Mayer IA, Estrada MV, González-Ericsson PI, Isakoff SJ, Forero-Torres A, Won H, Sanders ME, Solit DB, Berger MF, Cantley LC, Winer EP, Arteaga CL, Balko JM. PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. NPJ Breast Cancer 2019, 5: 31. PMID: 31552290, PMCID: PMC6757060, DOI: 10.1038/s41523-019-0126-6.
  • Adjuvant Chemotherapy for Older Patients With Breast Cancer: When Is the Pain Worth the Gain?Freedman RA, Winer EP. Adjuvant Chemotherapy for Older Patients With Breast Cancer: When Is the Pain Worth the Gain? Journal Of The National Cancer Institute 2020, 112: 551-552. PMID: 31612212, PMCID: PMC7301071, DOI: 10.1093/jnci/djz192.
  • Aggressive Subsets of Metastatic Triple Negative Breast Cancer.Singh J, Asad S, Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, Winer EP, Lin NU, Partridge AH, Overmoyer B, Stover DG. Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clinical Breast Cancer 2020, 20: e20-e26. PMID: 31631016, DOI: 10.1016/j.clbc.2019.06.012.
  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology 2020, 21: 44-59. PMID: 31786121, DOI: 10.1016/S1470-2045(19)30689-8.
  • Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). Journal Of Clinical Pharmacology 2020, 60: 444-452. PMID: 31802506, PMCID: PMC7064382, DOI: 10.1002/jcph.1559.
  • Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AH. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 725-733. PMID: 31809240, PMCID: PMC7048163, DOI: 10.1200/JCO.19.01959.
  • De-escalating Breast Cancer Surgery-Where Is the Tipping Point?Morrow M, Winer EP. De-escalating Breast Cancer Surgery-Where Is the Tipping Point? JAMA Oncology 2020, 6: 183-184. PMID: 31830209, DOI: 10.1001/jamaoncol.2019.4849.
  • Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 1284-1292. PMID: 32125937, PMCID: PMC7164489, DOI: 10.1200/JCO.19.00510.
  • Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2020, 31: 582-589. PMID: 32178964, DOI: 10.1016/j.annonc.2020.02.003.
  • The legacy of Professor Aron Goldhirsch.Gelber RD, Coates AS, Gelber S, Orecchia R, Veronesi P, Di Leo A, Colleoni M, Winer EP, Burstein HJ, Viale G, Senn HJ, Piccart M, Curigliano G. The legacy of Professor Aron Goldhirsch. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2020, 31: 671-673. PMID: 32217075, DOI: 10.1016/j.annonc.2020.03.288.
  • Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study.Vaz-Luis I, Barroso-Sousa R, Di Meglio A, Hu J, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, O'Neil K, Partridge A, Burstein H, Waks AG, Trippa L, Tolaney SM, Hassett M, Winer EP, Lin NU. Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 2390-2397. PMID: 32330102, PMCID: PMC7367545, DOI: 10.1200/JCO.19.02484.
  • De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ-Reply.Morrow M, Winer E. De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ-Reply. JAMA Oncology 2020, 6: 1118. PMID: 32379278, DOI: 10.1001/jamaoncol.2020.0819.
  • The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu QS, Batist G, Hughes ME, Kremer JD, Garraway LA, Winer EP, Tolaney SM, Lin NU, Buchanan SG, Wagle N. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discovery 2020, 10: 1174-1193. PMID: 32404308, PMCID: PMC8815415, DOI: 10.1158/2159-8290.CD-19-1390.
  • Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond.Freedman RA, Sedrak MS, Bellon JR, Block CC, Lin NU, King TA, Minami C, VanderWalde N, Jolly TA, Muss HB, Winer EP. Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. Journal Of The National Cancer Institute 2021, 113: 355-359. PMID: 32449757, PMCID: PMC7313961, DOI: 10.1093/jnci/djaa079.
  • Therapy for HER2-Positive Metastatic Breast Cancer. Reply.Winer EP. Therapy for HER2-Positive Metastatic Breast Cancer. Reply. The New England Journal Of Medicine 2020, 382: e98. PMID: 32558480, DOI: 10.1056/NEJMc2004854.
  • Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.Magbanua MJM, Savenkov O, Asmus EJ, Ballman KV, Scott JH, Park JW, Dickler M, Partridge A, Carey LA, Winer EP, Rugo HS. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 4911-4920. PMID: 32586939, PMCID: PMC7501177, DOI: 10.1158/1078-0432.CCR-20-1329.
  • Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers.Knelson LP, Cukras AR, Savoie J, Agarwal A, Guo H, Hu J, Fell G, Lederman R, Hughes ME, Winer EP, Lin NU, Tolaney SM. Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. Clinical Breast Cancer 2020, 20: 395-401.e3. PMID: 32605813, DOI: 10.1016/j.clbc.2020.05.001.
  • Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.Mao P, Cohen O, Kowalski KJ, Kusiel JG, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung J, Freeman S, Rozenblatt-Rosen O, Miller VA, Piccioni F, Root DE, Regev A, Winer EP, Lin NU, Wagle N. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 5974-5989. PMID: 32723837, DOI: 10.1158/1078-0432.CCR-19-3958.
  • Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal Of The National Cancer Institute 2021, 113: 443-452. PMID: 32770247, PMCID: PMC8023821, DOI: 10.1093/jnci/djaa113.
  • A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.Amiri-Kordestani L, Xie D, Tolaney SM, Bloomquist E, Tang S, Ibrahim A, Goldberg KB, Theoret MR, Pazdur R, Sridhara R, Winer EP, Beaver JA. A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2020, 31: 1704-1708. PMID: 32866625, DOI: 10.1016/j.annonc.2020.08.2106.
  • Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib.Batalini F, Moulder SL, Winer EP, Rugo HS, Lin NU, Wulf GM. Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib. JCO Precision Oncology 2020, 4 PMID: 32923889, PMCID: PMC7446424, DOI: 10.1200/PO.19.00403.
  • Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin NU, Winer EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Research And Treatment 2021, 185: 215-227. PMID: 32939592, DOI: 10.1007/s10549-020-05931-9.
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2020, 31: 1623-1649. PMID: 32979513, PMCID: PMC7510449, DOI: 10.1016/j.annonc.2020.09.010.
  • Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Naït Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber RD, Davidson NE, Norton L, Winer EP. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 4120-4129. PMID: 33052755, DOI: 10.1200/JCO.20.01382.
  • Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.Sella T, Gelber SI, Poorvu PD, Kim HJ, Dominici L, Guzman-Arocho YD, Collins L, Ruddy KJ, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Snow C, Jakubowski DM, Russell CA, Winer EP, Rosenberg SM, Partridge AH. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Research And Treatment 2021, 186: 157-165. PMID: 33150547, DOI: 10.1007/s10549-020-05989-5.
  • Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 983-991. PMID: 33257427, PMCID: PMC7887044, DOI: 10.1158/1078-0432.CCR-20-3089.
  • Perceptions of patients with early stage breast cancer toward research biopsies.Seah DS, Leone JP, Openshaw TH, Scott SM, Tayob N, Hu J, Lederman RI, Frank ES, Sohl JJ, Stadler ZK, Erick TK, Silverman SG, Peppercorn JM, Winer EP, Come SE, Lin NU. Perceptions of patients with early stage breast cancer toward research biopsies. Cancer 2021, 127: 1208-1219. PMID: 33320362, PMCID: PMC8247276, DOI: 10.1002/cncr.33371.
  • Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology 2021, 22: 212-222. PMID: 33460574, DOI: 10.1016/S1470-2045(20)30642-2.
  • Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement.Freedman RA, Minami CA, Winer EP, Morrow M, Smith AK, Walter LC, Sedrak MS, Gagnon H, Perilla-Glen A, Wildiers H, Wildes TM, Lichtman SM, Loh KP, Brain EGC, Ganschow PS, Hunt KK, Mayer DK, Ruddy KJ, Jagsi R, Lin NU, Canin B, LeStage BK, Revette AC, Schonberg MA, Keating NL. Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. JAMA Oncology 2021, 7: 609-615. PMID: 33507222, PMCID: PMC8944384, DOI: 10.1001/jamaoncol.2020.7582.
  • Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.Laws A, Garrido-Castro A, Poorvu P, Winer E, Mittendorf E, King T. Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. Oncology (Williston Park, N.Y.) 2021, 35: 77-84. PMID: 33577165, DOI: 10.46883/ONC.2021.3502.0077.
  • Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. The Lancet. Oncology 2021, 22: 499-511. PMID: 33676601, DOI: 10.1016/S1470-2045(20)30754-3.
  • Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer.Collier KA, Asad S, Tallman D, Jenison J, Rajkovic A, Mardis ER, Parsons HA, Tolaney SM, Winer EP, Lin NU, Ha G, Adalsteinsson VA, Stover DG. Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology 2021, 5 PMID: 34849445, PMCID: PMC8624042, DOI: 10.1200/PO.21.00104.
  • Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, Vedula RS, Lindsley RC, Copson KM, Charles A, Marty F, Neuberg D, DeAngelo DJ, Stone RM, Luskin MR, Issa NC, Garcia JS. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leukemia & Lymphoma 2022, 1-8. PMID: 35289704, DOI: 10.1080/10428194.2022.2047964.
  • Temporal and spatial topography of cell proliferation in cancer.Gaglia G, Kabraji S, Rammos D, Dai Y, Verma A, Wang S, Mills CE, Chung M, Bergholz JS, Coy S, Lin JR, Jeselsohn R, Metzger O, Winer EP, Dillon DA, Zhao JJ, Sorger PK, Santagata S. Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology 2022, 24: 316-326. PMID: 35292783, PMCID: PMC8959396, DOI: 10.1038/s41556-022-00860-9.
  • p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases.Ni J, Kabraji S, Xie S, Wang Y, Pan P, He X, Liu Z, Leone JP, Long HW, Brown MA, Winer EP, Dillon DAR, Lin NU, Zhao JJ. p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications 2022, 13: 1473. PMID: 35304445, PMCID: PMC8933392, DOI: 10.1038/s41467-022-29081-2.
  • The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers.Anderson KS, Erick TK, Chen M, Daley H, Campbell M, Colson Y, Mihm M, Zakka LR, Hopper M, Barry W, Winer EP, Dranoff G, Overmoyer B. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. Breast Cancer Research And Treatment 2022, 194: 65-78. PMID: 35482127, PMCID: PMC9046531, DOI: 10.1007/s10549-022-06562-y.
  • A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EP. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ Breast Cancer 2022, 8: 63. PMID: 35538105, PMCID: PMC9091255, DOI: 10.1038/s41523-022-00429-7.
  • STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications 2022, 13: 3022. PMID: 35641483, DOI: 10.1038/s41467-022-30568-1.
  • Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, Krop IE, Knape C, Feger U, Marsico G, Howarth K, Winer EP, Lin NU, Parsons HA. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, JCO2200908. PMID: 35658506, DOI: 10.1200/JCO.22.00908.
  • Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study.Stavrou E, Qiu J, Zafar A, Tramontano AC, Isakoff S, Winer E, Schrag D, Manz C. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. JCO Oncology Practice 2022, OP2200072. PMID: 35671420, DOI: 10.1200/OP.22.00072.
Edit Profile